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1 Abstract 
2 
3 Background: To simultaneously evaluate the relative efficacy of multiple 
4 
5 
6 pharmacological strategies for preventing contrast-induced acute kidney injury (CI- 
7 
8 
9 AKI). 
10 
11 
12 Study Design: Systematic review containing a Bayesian network meta-analysis of 
13 
14 randomized controlled trials (RCTs) 
15 
16 
17 Setting & Population: Participants undergoing diagnostic and/or interventional 
18 
19 
20 procedures with contrast media. 
21 
22 
23 Selection Criteria for Studies: RCTs comparing the active drug treatments with each 
24 
25 other or with hydration alone. 
26 
27 
28 Intervention: Any of the following drugs in combination with hydration: N- 
29 
30 
31 acetylcysteine (NAC), theophylline (aminophylline), fenoldopam, iloprost, 
32 
33 
34 alprostadil, prostaglandin E1, statins, statins plus NAC, bicarbonate sodium, 
35 
36 bicarbonate sodium plus NAC, ascorbic acid (vitamin C), tocopherol (vitamin E), 
37 
38 
39 alpha lipoic acid, atrial natriuretic peptide, B-type natriuretic peptide, and carperitide. 
40 
41 
42 Outcomes: The occurrence of CI-AKI 
43 
44 
45 Results: The trial network included 150 trials with 31,631 participants and 4,182 CI- 
46 
47 AKI events assessing 12 different interventions. Compared with hydration, the odds 
49 
50 ratios (ORs) for CI-AKI were 0.31 (95% credible interval 0.14 to 0.60) for high-dose 
51 
52 
53 statin plus NAC, 0.37 (0.19 to 0.64) for high-dose statins alone, 0.37 (0.17 to 0.72) for 
54 
55 
56 prostaglandins, 0.48 (0.26 to 0.82) for theophylline, 0.62 (0.40 to 0.88) for 
57 
58 
bicarbonate sodium plus NAC, 0.67 (0.54 to 0.81) for NAC alone, 0.64 (0.41 to 0.95) 
60 
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1 for vitamins and its analogues, 0.70 (0.29 to 1.37) for natriuretic peptides, 0.69 (0.31 
2 
3 to 1.37) for fenoldopam, 0.78 (0.59 to 1.01) for bicarbonate sodium, and 0.98 (0.41 to 
4 
5 
6 2.07) for low dose statin. High-dose statin plus NAC or high-dose statin alone were 
7 
8 
9 likely to be ranked the best or the second best for preventing CI-AKI. The overall 
10 
11 
12 results were not materially changed in meta-regressions, subgroup and sensitivity 
13 
14 analyses. 
15 
16 
17 Limitations: Patient-level data was unavailable. Unable to include some treatment 
18 
19 
20 agents, low event rates, and imbalanced distribution of participants among treatment 
21 
22 
23 strategies. 
24 
25 Conclusions: High-dose statins plus hydration with or without NAC might be the 
26 
27 
28 preferred treatment strategy to prevent CI-AKI in patients undergoing diagnostic 
29 
30 
31 and/or interventional procedures requiring contrast media. 
32 
33 
34 Index Words: 
35 
36 contrast-induced acute kidney injury (CI-AKI), contrast media, kidney disease, acute 
37 
38 
39 kidney failure, statins, hydroxymethylglutaryl-CoA reductase inhibitor, atorvastatin, 
40 
41 
42 rosuvastatin, simvastatin, serum creatinine, cardiovascular events, systematic review. 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
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1 Introduction 
2 
3 With the steady increase in the rates of diagnostic and/or interventional procedures 
4 
5 
6 with contrast media (CM), contrast-induced acute kidney injury (CI-AKI) has become 
7 
8 
9 the third most common cause of AKI in hospitalized patients.1 CI-AKI leads to 
10 
11 
prolonged hospitalization, increased costs, and increased morbidity and mortality.2 
13 
14 Factors associated with the risk of CI-AKI include pre-existing renal functional 
15 
16 
17 impairment, diabetes, hypertension, chronic heart failure, advanced age, volume 
18 
19 
20 depletion, haemodynamic instability, use of concurrent nephrotoxic medications, and 
21 
22 
large volume or high osmolality of CM.3,4 
24 
25 Minimization of the CM dose and the use of iso-osmolar or low-osmolar CM are 
26 
27 
28 recommended as non-pharmacological precautions, and numerous pharmacological 
29 
30 
31 strategies for preventing CI-AKI have been evaluated. In 2008, a comprehensive 
32 
33 
34 meta-analysis of randomized controlled trials (RCTs) concluded that N acetylcysteine 
35 
36 (NAC) in combination with hydration was more effective than hydration alone.5 
37 
38 
39 However, due to the lack of head-to-head comparisons between treatment agents, 
40 
41 
42 traditional pairwise meta-analyses could not be used to simultaneously synthesize all 
43 
44 
45 evidence and generate clear hierarchies for the efficacy of different treatments.5-8 
46 
47 Therefore, the choice of the best treatment in practice is generally based on subjective 
49 
50 judgement, and objective information regarding the relative efficacy of different 
51 
52 
53 interventions would help the development of clinical practice guidelines for 
54 
55 
56 preventing CI-AKI. 
57 
58 
Bayesian network meta-analysis, also known as mixed treatment comparison, 
60 
61 
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1 enables indirect comparison using a common comparator, and combines direct and 
2 
3 indirect comparisons to synchronously assess multiple treatments.9-11 The usefulness 
4 
5 
6 of this method has been demonstrated in many studies on various medical conditions 
7 
8 
9 and interventions.12-14 This systematic review and network meta-analysis therefore 
10 
11 
12 aims to compare the relative efficacy of different pharmacological interventions for 
13 
14 preventing CI-AKI by means of network meta-analysis within a Bayesian framework. 
15 
16 
17 
18 
19 
20 Methods 
21 
22 
23 Data Sources and Searches 
24 
25 This systematic review was performed according to a pre-specified protocol (Item 
26 
27 
28 S1) and the reporting was in line with PRISMA guidelines.15 We searched MEDLINE 
29 
30 
31 via Ovid (from 1946 to May 2016), Embase (from 1966 to May 2016), and the 
32 
33 
34 Cochrane Library database (Cochrane Central Register of Controlled Trials; before 
35 
36 May 2016) for RCTs of CI-AKI prevention, without any language restrictions (see 
37 
38 
39 Item S1 for full search terms). The ClinicalTrials.gov website was also searched for 
40 
41 
42 RCTs that were registered as completed but not yet published. 
43 
44 
45 
46 
47 
Study Selection 
49 
50 We included RCTs that evaluated any of the following drugs in combination with 
51 
52 
53 hydration: NAC, theophylline (aminophylline), fenoldopam, iloprost, alprostadil, 
54 
55 
56 prostaglandin E1, statins, statins plus NAC, bicarbonate sodium, bicarbonate sodium 
57 
58 
plus NAC, ascorbic acid (vitamin C), vitamin E or its analogues (tocopherol), alpha 
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1 lipoic acid, atrial natriuretic peptide, B-type natriuretic peptide, and carperitide. RCTs 
2 
3 comparing the above active drug treatments with each other or with hydration were 
4 
5 
6 eligible. We excluded studies that contained only one or none of the above treatments. 
7 
8 
9 Eligible participants were those who underwent diagnostic and/or interventional 
10 
11 
12 procedures with CM, such as diagnostic coronary or peripheral arterial angiography or 
13 
14 percutaneous intervention, ventriculography, enhanced CT, intravenous pyelography, 
15 
16 
17 and other relevant procedures. 
18 
19 
20 The treatment groups were classified into 12 categories according to the drug 
21 
22 
23 species and/or dose: 1. atrial natriuretic peptide, B-type natriuretic peptide and 
24 
25 carperitide were classified into natriuretic peptide; 2. ascorbic acid (vitamin C, 
26 
27 
28 tocopherol and alpha-lipoic acid were classified into vitamins and its analogues; 3. 
29 
30 
31 simvastatin 40-80 mg, rosuvastatin 20-40 mg and atorvastatin 40-80 mg were known 
32 
33 
34 as high-dose statin; 4. low-dose statin included simvastatin 10-20 mg, rosuvastatin 10 
35 
36 mg and atorvastatin 10-20 mg; 5. iloprost, alprostadil, misoprostol and prostaglandin 
37 
38 
39 E1 were categorized into prostaglandin. The other seven treatments included: 6. 
40 
41 
42 theophylline (aminophylline); 7. NAC; 8. fenoldopam; 9. bicarbonate sodium; 10. 
43 
44 
45 bicarbonate sodium plus NAC; 11. high-dose statin plus NAC; 12. hydration 
46 
47 
Data Extraction and Quality Assessment 
49 
50 Study selection, data extraction, and quality assessment were performed 
51 
52 
53 independently by two investigators (XL.S and XF.X) according to the pre-specified 
54 
55 
56 study protocol (Item S1). The two investigators screened the titles and abstracts of the 
57 
58 
records identified by the search strategies for eligibility. Disagreements were resolved 
60 
61 
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1 by discussion with a third reviewer (LJ.L). Data on pre-specified variables from the 
2 
3 included studies were extracted into a computerized spreadsheet. 
4 
5 
6 The outcome used was the development of CI-AKI, defined as an absolute increase in 
7 
8 
9 the baseline serum creatinine level of greater than 44.2 μmol/L (0.5 mg/dL) or a 
10 
11 
12 relative increase of greater than 25%, typically within 48-72 h after contrast 
13 
14 injection.16,17 If data was not available for the first 48-72 h after the treatment, we 
15 
16 
17 used data obtained within the first 5 days of treatment (the data point closest to 48-72 
18 
19 
20 h was given preference).18  If different measurement index (eg. eGFR, Ccr) or standard 
21 
22 
23 was applied, we extracted data according to one defined by authors of the included 
24 
25 studies. 
26 
27 
28 We assessed sources of bias using the Cochrane Collaboration risk-of-bias tool,19 
29 
30 
31 including an assessment of financial conflicts of interest.20 We developed operational 
32 
33 
34 definitions for high, low, and unclear risk of bias for each of the eight validity 
35 
36 domains (Item S2). 
38 
39 Data Synthesis and Analysis 
40 
41 
42 We used odds ratio (OR) and its 95% credible intervals (CrIs) to measure the 
43 
44 
45 relative effect of different treatments on CI-AKI outcome. Before conducting network 
46 
47 meta-analysis, we conducted conventional pairwise meta-analyses for treatments that 
49 
50 were directly compared in RCTs. We used fully Bayesian method (FB), assuming a 
51 
52 
53 binomial likelihood on the log-odds scale, in pairwise meta-analyses through 
54 
55 
56 WinBUGS 1.4.3.21,22 To investigate heterogeneity in conventional pairwise meta- 
57 
58 
analysis, we used STATA 12.0 to conduct meta-regression of direct comparisons 
60 
61 
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1 based on empirical Bayes method, and estimated I2, tau2  and Q value. 
2 
3 Network meta-analysis was conducted by using random-effects model within a 
4 
5 
6 Bayesian framework, assuming a binomial likelihood and using WinBUGS 1.4.3 and 
7 
8 
9 R2WinBUGS package of R software 3.1.1 according to a pre-defined protocol (Item 
10 
11 
12 S1). We used non-informative priors with vague normal (mean, 0; variance, 100,000) 
13 
14 and uniform (0 to 5) prior distributions for parameters such as means and standard 
15 
16 
17 deviations, respectively.11 For each analysis, we generated 200,000 simulations for 
18 
19 
20 each of the two sets of different initial values, and discarded the first 80,000 
21 
22 
23 simulations as the burn-in period. Convergence was reached when Rhat, the potential 
24 
25 scale reduction factor is close to 1 for each of the parameters using the Brooks– 
26 
27 
28 Gelman–Rubin statistic.23 We used the surface under the cumulative ranking 
29 
30 
31 (SUCRA) probabilities to rank the treatments.24 
32 
33 
34 Inconsistency refers to differences in effect estimates between direct and indirect 
35 
36 comparisons, which could be assessed when three treatments are connected within a 
37 
38 
39 loop.25,26 For each closed loop, we estimated the absolute difference between the 
40 
41 
42 direct and indirect comparisons, which is termed inconsistency factor. Inconsistent 
43 
44 
45 loops were identified by a significant disagreement (inconsistency factor and its 95% 
46 
47 CI that excludes 0) between direct and indirect evidence.25,27,28 As a whole, 
49 
50 inconsistency was also assessed by the comparison between the consistency model 
51 
52 
53 and inconsistency model of the network meta-analysis using deviance information 
54 
55 
56 criterion (DIC). A lower value of the DIC suggests a more parsimonious model. If the 
57 
58 
trade-off between model fit and complexity favours the model with assumes 
60 
61 
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1 inconsistency, then the assumption of consistency is likely to be violated.12,29 
2 
3 We carried out the following pre-specified sensitivity analyses: exclusion of trials 
4 
5 
6 with sample sizes less than 50 in order to reduce small study effect and publication 
7 
8 
9 bias; exclusion of trials with high-osmolar and unspecified CM types; and exclusion 
10 
11 
12 of data from patients with non-DM (Item S1). Other analyses were post-hoc: 
13 
14 exclusion of trials evaluating only patients with normal kidney function, published 
15 
16 
17 before 2004, with oral hydration and unspecified hydration agent. 
18 
19 
20 Pre-specified multiple-treatments meta-regression and subgroup analyses were 
21 
22 
23 conducted by several major covariates, such as mean CM dose, mean age, baseline 
24 
25 serum creatinine concentration, different CI-AKI definitions, and different radiologic 
26 
27 
28 procedures with CM (Item S1). Post-hoc subgroup analysis was conducted by types 
29 
30 
31 of CM and different hydration agents. 
32 
33 
34 The models used, the WinBUGS codes, and R routines for all results are presented 
35 
36 in detail and exemplified in http://www.mtm.uoi.gr. and http://www.nicedsu.org.uk. A 
37 
38 
39 short summary is supplied in Item S3. 
40 
41 
42 
43 
44 
45 Results 
46 
47 The literature search yielded 4144 articles. We assessed the full text of 396 of these 
49 
50 articles for eligibility, and eventually included 150 RCTs in the network meta-analysis 
51 
52 
53 (Figure 1, see details of included studies in Table S1). CI-AKI was measured 
54 
55 
56 according to the difference between the baseline serum creatinine level and the level 
57 
58 
within 48 h-72h in 120 studies. In 30 trials, CI-AKI was defined according to different 
60 
61 
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1 points in time and measurements (eg. eGFR, Ccr), or the determination method was 
2 
3 not specified. Of the included RCTs, 104 trials included patients with impaired renal 
4 
5 
6 function, 37 trials included patients with normal or impaired renal function, and 9 
7 
8 
9 trials included only patients with normal renal function. Participants were recruited at 
10 
11 
12 an average age of 67 years, and male participants accounted for 68% of the total 
13 
14 population. A total of 11 types of CM were used, including iso-osmolar, low- 
15 
16 
17 osmolar, and high-osmolar media. The dosing regimens and types of CM used in the 
18 
19 
20 included trials are detailed in Table S1. 
21 
22 
23 The methodological quality of the included trials was not high overall and varied 
24 
25 substantially (Item S2, Figure S1, S2). The proportion of trials with a low risk of bias 
26 
27 
28 was 53% in terms of random sequence generation, 54% in terms of allocation 
29 
30 
31 concealment, 49% in terms of blinding of both participants and health care 
32 
33 
34 professionals, 59% in terms of blinding of outcome assessors, 48% in terms of 
35 
36 attrition, and 35% in terms of reporting bias. With respect to conflicts of interest, 
37 
38 
39 about 50% of RCTs were funded by pharmaceutical industry and 51% reported 
40 
41 
42 author-industry financial relationships. In order to investigate reporting/published 
43 
44 
45 bias, we searched and found 21 protocols for 396 full-text reviewed articles. In studies 
46 
47 
without reporting the outcome of interest, we didn’t find any pre-planned CI-AKI 
49 
50 outcome. 
51 
52 
53 A total of 4,182 CI-AKI events were reported in 150 trials with 31,631 participants. 
54 
55 
56 Figure 2 shows all comparisons that were analysed in the network meta-analysis. The 
57 
58 
results of available direct comparisons are shown in Figure 3 and Table S2, and the 
60 
61 
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1 results of testing heterogeneity (I2, tau2  and Q) within treatment strategies were 
2 
3 showed in Table S2. We summarized the results of random-effects consistency 
4 
5 
6 network meta-analysis in Figure 3. The effects of individual treatment strategies 
7 
8 
9 compared with hydration on preventing CI-AKI are presented in Figure 4. Compared 
10 
11 
12 with hydration alone, high-dose statin plus NAC, high-dose statin, prostaglandin, 
13 
14 theophylline, bicarbonate sodium plus NAC, vitamins and their analogues and NAC 
15 
16 
17 alone (all in combination with hydration) statistically significantly reduced the risk of 
18 
19 
20 CI-AKI (Figure 3 and Figure 4). In addition, high-dose statins were significantly 
21 
22 
23 more effective than low-dose statins (OR: 0.42; 95% CrI: 0.19 to 0.79), NAC (OR: 
24 
25 0.51; 95% CrI: 0.29 to 0.98) and bicarbonate sodium(OR: 0.49; 95% CrI: 0.23 to 
26 
27 
28 0.86). Prostaglandin was significantly more effective than bicarbonate sodium (OR: 
29 
30 
31 0.49; 95% CrI: 0.22 to 0.98). High-dose statin combined with NAC was statistically 
32 
33 
34 more effective than NAC (OR: 0.41; 95% CrI: 0.22 to 0.86), low-dose statins (OR: 
35 
36 0.28; 95% CrI: 0.12 to 0.99), bicarbonate sodium plus NAC (OR: 0.51; 95% CrI: 0.24 
37 
38 
39 to 0.99) and bicarbonate sodium alone (OR: 0.35; 95% CrI: 0.18 to 0.79). 
40 
41 
42 High-dose statin plus NAC (SUCRA: 0.90) and high-dose statin (SUCRA: 0.83) 
43 
44 
45 were most likely to be ranked the best or second best (Figure S3). They were 
46 
47 followed by prostaglandins (SUCRA: 0.82) and theophyllines (SUCRA: 0.70). 
49 
50 SUCRAs (range: 0.41 to 0.49) and rankings were similar for bicarbonate sodium plus 
51 
52 
53 NAC, vitamins and its analogues, natriuretic peptides, fenoldopam and NAC. 
54 
55 
56 Hydration alone was ranked as the least effective treatment. 
57 
58 
The DIC value was lowest in the random consistency model than in the other three 
60 
61 
11 / 29 
62 
63 
64 
65 
48 
59 
1 models, which indicated that the former was the preferred model with a better trade- 
2 
3 off between model fit and complexity (Table S3). However, significant discrepancy 
4 
5 
6 between the direct and indirect comparisons was identified in two of the 13 loops 
7 
8 
9 (Figure S4). The two inconsistent loops consisted of (1) vitamins and its analogues 
10 
11 
12 vs. bicarbonate sodium plus NAC vs. hydration; and (2) vitamins and its analogues vs. 
13 
14 bicarbonate sodium plus NAC vs. NAC. Further investigation was performed, but we 
15 
16 
17 were unable to identify possible sources of inconsistency. As the number of relevant 
18 
19 
20 studies in the inconsistent loops was small, the extent of inconsistency was not 
21 
22 
23 substantial enough to affect the overall results. 
24 
25 Treatments with high-dose statin plus NAC or high-dose statin were consistently 
26 
27 
28 associated with the lowest or second lowest incidence of CI-AKI in sensitivity 
29 
30 
31 analyses, meta-regression, and subgroup analyses (Table S4 and S5). A notable 
32 
33 
34 exception is that the effects of vitamins and its analogues became statistically non- 
35 
36 significant compared with hydration in some sensitivity and subgroup analyses.. 
37 
38 
39 When the analysis included only DM participants (38 trials, 7984 patients and 826 
40 
41 
42 events), credible intervals were wide and all ORs were no longer statistically 
43 
44 
45 significant due to the reduced sample size, although high-dose statin plus NAC and 
46 
47 high-dose statin remained the first and the second ranking among all treatment 
49 
50 strategies. None of the other sensitivity, meta-regression, or subgroup analyses led to 
51 
52 
53 important changes in the overall results (Table S4 and S5). 
54 
55 
56 
57 
58 
Discussion 
60 
61 
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1 Our study included 150 trials with more than 30,000 participants and a total of 
2 
3 4,182 CI-AKI events. The mixed treatment comparison of 12 treatment strategies for 
4 
5 
6 preventing CI-AKI confirmed that treatment with a high-dose statin alone or in 
7 
8 
9 combination with NAC (both in combination with hydration) during CM 
10 
11 
12 administration significantly reduced the risk of CI-AKI compared with hydration 
13 
14 alone. Compared with other protective regimens, oral administration of high-dose 
15 
16 
17 statins is simple and convenient. These results indicate an opportunity to potentially 
18 
19 
20 simplify prevention strategies for CI-AKI. Our analysis also found a number of other 
21 
22 
23 strategies that appeared to be superior to hydration alone, including prostaglandins, 
24 
25 theophylline, bicarbonate sodium plus NAC, vitamins and their analogues and NAC. 
26 
27 
28 A recent comprehensive pairwise meta-analysis reported that the greatest reduction 
29 
30 
31 in CI-AKI was seen with NAC plus hydration and with statins plus NAC plus 
32 
33 
34 hydration in patients receiving CM.30  Our study simultaneously compared multiple 
35 
36 treatment strategies using Bayesian network meta-analysis method, and found that 
37 
38 
39 patients using CM were most likely to benefit from high-dose statin. The results of the 
40 
41 
42 current study were similar to findings from previous primary studies31–34  and meta- 
43 
44 
45 analyses,6,35–37 which suggested that short-term prophylaxis with high-dose statins led 
46 
47 to a significant reduction in the risk of CI-AKI. In contrast, the meta-analysis by 
49 
50 Zhang T et al.38  found no significant reduction in the incidence of CI-AKI with statins 
51 
52 
53 treatment, as determined using the pooled estimate of the included trials. However, it 
54 
55 
56 should be noted that the meta-analysis by Zhang T et al incompletely include relevant 
57 
58 
randomized trials.39,40 
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1 Pre-existing renal dysfunction is an independent predictor of CI-AKI.41 Findings 
2 
3 from some previous pairwise meta-analyses35,36  suggested that the use of statins may 
4 
5 
6 not be effective for patients with pre-existing chronic kidney disease (CKD). Our 
7 
8 
9 meta-regression analyses found that baseline serum creatinine concentration as a 
10 
11 
12 continuous covariate was not a statistically significant effect-modifier (regression 
13 
14 coefficient: 0.09; 95% CrI: -1.86 to 1.90). Consistent with our results, the TRACK-D 
15 
16 
17 study involving almost 3,000 DM participants with mild-to-moderate CKD 
18 
19 
20 demonstrated a significant reduction in the relative risk of CI-AKI with rosuvastatin 
21 
22 
therapy.40 
24 
25 Although the pathogenesis of CI-AKI is not completely understood, multiple 
26 
27 
28 mechanisms are probably involved, including direct toxicity of CM on the renal 
29 
30 
31 tubular epithelium, inflammatory reactions, oxidative stress, ischemic injury, and 
32 
33 
34 renal tubular obstruction.42 Statins may have multiple non-lipid-lowering effects, such 
35 
36 as enhancement of endothelial nitric oxide production,43–45 anti-inflammatory and 
37 
38 
39 anti-oxidative actions,46,47 and apoptosis prevention.34 These pleiotropic effects of 
40 
41 
42 statins could mediate the reduction of CI-AKI risk after iodinated contrast 
43 
44 
45 administration. Furthermore, use of antioxidants (eg, vitamins and its analogues, 
46 
47 NAC) might be an effective strategy to prevent CI-AKI, considering their roles in 
49 
50 attenuating the oxidative damage from radiocontrast. 
51 
52 
53 Apart from high-dose statins and high-dose statins plus NAC, prostaglandins had 
54 
55 
56 better effects than other treatment strategies, based on evidence from five trials that 
57 
58 
included a total of 943 participants and evaluated four classes of prostaglandins. 
60 
61 
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1 Adequate renal prostaglandin levels may counteract contrast-induced renal 
2 
3 vasoconstriction and selective renal tubular epithelial cell toxicity.48 
4 
5 
6 As a non-selective adenosine receptor antagonist, theophylline may help attenuate 
7 
8 
9 the vasoconstrictive tendencies observed after CM administration.49,50 A previous 
10 
11 
12 pairwise meta-analysis also showed that theophylline administration reduced the 
13 
14 incidence of CI-AKI compared with the control group.51 Although pre-interventional 
15 
16 
17 theophylline administration might be helpful in patients with CM, the possibility of 
18 
19 
20 cardiovascular side-effects and the interactions with numerous drugs associated with 
21 
22 
theophylline should be recognized.52,53 
24 
25 Many but not all studies reported that NAC has a protective effect on CI-AKI when 
26 
27 
28 administered before the onset of renal insult. Of the 11 previous meta-analyses 
29 
30 
31 published on this subject, seven found a net benefit of NAC in CI-AKI prevention. 
32 
33 
34 However, due to statistically significant heterogeneity and possible publication bias, 
35 
36 the benefit of NAC might have been overestimated.54 With low the strength of 
37 
38 
39 evidence, Kidney Disease Improving Global Outcomes Clinical Practice Guideline for 
40 
41 
42 CI-AKI suggests the use of oral N-acetylcysteine plus hydration. Another meta- 
43 
44 
45 analysis found that a combination of NAC and sodium bicarbonate substantially 
46 
47 reduced CI-AKI risk compared with NAC alone.55 However, we found that both 
49 
50 sodium bicarbonate plus NAC and vitamins and their analogues were involved in 
51 
52 
53 significant inconsistent loops, and results for vitamins and their analogues were not 
54 
55 
56 robust in sensitivity and subgroup analyses. 
57 
58 
This network meta-analysis provides a most comprehensive picture of the 
60 
61 
15 / 29 
62 
63 
64 
65 
12 
48 
59 
1 likelihood of a range of treatments to prevent CI-AKI, and reports the results of mixed 
2 
3 comparisons of multiple treatments that have been rarely compared in head to head 
4 
5 
6 trials. We also report the ranking probability for all 12 treatment agents. However, 
7 
8 
9 treatment rankings derived from network meta-analyses may have a substantial degree 
10 
11 
of imprecision,56  and the results in terms of treatment ranking should be interpreted 
13 
14 with caution. 
15 
16 
17 Our study has several limitations. First, the trial network could not include some 
18 
19 
20 treatment agents, such as Na/K citrate,57 allopurinol,58 statin plus alsprostadil,59  that 
21 
22 
23 may be efficacious but were evaluated in only one or two small trials without a 
24 
25 connection with other commonly used treatments. For many specific treatments, the 
26 
27 
28 number of patients and events in the available trials may not be sufficient to form a 
29 
30 
31 well-connected network for meta-analysis. We therefore combined drugs with the 
32 
33 
34 same types and similar mechanism of action and evaluated treatment effects of major 
35 
36 drug classes. Second, many of the included studies showed low CI-AKI event rates or 
37 
38 
39 no events at all in one or both trial arms, and there was an imbalance in the 
40 
41 
42 distribution of participants among some of the treatment strategies. Consequently, the 
43 
44 
45 uncertainty in the analyses was increased, resulting in wide CrIs for several treatment 
46 
47 comparisons. Third, the absence of patient-specific data, varying quality and design of 
49 
50 the included studies are limitations common to all meta-analyses. To at least partly 
51 
52 
53 nullify the latter factors, we included only RCTs. Furthermore, the meta-regression 
54 
55 
56 based on trial-level covariates rather than individual patient data might bring the 
57 
58 
ecological fallacy.60 Fourth, we included only published studies in this analysis, and 
60 
61 
16 / 29 
62 
63 
64 
65 
48 
59 
1 reporting bias could not be ruled out because not all studies reported CI-AKI 
2 
3 outcome, especially when CI-AKI events were not primary end points. 
4 
5 
6 Further studies with head-to-head comparisons of statins at both high and low doses 
7 
8 
9 were needed to illuminate whether important differences exist in their abilities to 
10 
11 
12 reduce CI-AKI risk and whether dose matters. Prospective randomized trials should 
13 
14 focus on relatively homogeneous patient populations, such as DM, or whether patients 
15 
16 
17 with different stages of CKD would benefit similarly or differently from peri- 
18 
19 
20 procedural statin therapy. Future studies are also needed to test effects of 
21 
22 
23 combinations of different strategies shown to be beneficial in this analysis, and to 
24 
25 uncover possible mechanisms. 
26 
27 
28 Our Bayesian network meta-analysis indicates the effects and superiority of using a 
29 
30 
31 high-dose statin plus hydration with or without NAC in patients undergoing 
32 
33 
34 diagnostic and/or interventional procedures requiring CM. The results should be 
35 
36 interpreted with caution due to important data and methodological limitations. 
37 
38 
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40 defining treatment is compared with the column-defining treatment,  and  ORs   lower 
41 than 1 favor the row-defining treatment. To obtain ORs for comparisons in the opposite 
42 
43 direction,  reciprocals  should  be  taken.  Significant  results  are  in  bold.  The direct 
44 comparisons within two inconsistent loops are underlined. 
45 BIC,   Bicarbonate   sodium;   BIC+NAC,   Bicarbonate   sodium   plus   NAC;  FEN, 
46 
47 Fenoldopam; HST, High-dose statin; HST+NAC, High-dose statin plus NAC;    HYD, 
48 Hydration; LST,  Low-dose statin; NAC, N-acetylcysteine; NAP,  Natriuretic  peptide; 
49 PRO, Prostaglandin; THE, Theophylline; VIT, Vitamins and its analogues. 
51 
52 Figure 4: Forest plot for efficacy of 11 active drugs compared with hydration 
53 
54 Treatments are ranked according to their OR values(vs.hydration). 
55 CrI, credible interval. SUCRA, surface under the cumulative ranking curve   measure. 
56 NAC, N-acetylcysteine. OR, odds ratio. 
57 
58 
59 
60 
61 
26 / 29 
62 
63 
64 
65 
6 
10 
17 
21 
28 
39 
54 
1 
2 
3 
4 
5 
Supplemental Material 
7 
8 Table S1: Description of included studies 
9 ALA, alpha-lipoic acid; ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; 
11 CI-AKI, contrast-induced acute kidney injury; Crcl, Creatinine clearance rate;  eGFR, 
12 estimated glomerular   filtration rate;   NA,   no   available;   NAC,   N-acetylcysteine; 
13 
14 NaHCO3, bicarbonate sodium; Scr, Serum creatinine. 
15 
16 
Table S2: Meta-analytic results of traditional pairwise meta-analysis 
18 Abbreviations: CI, confidence interval; N, number of trials; n, number of patients; NA, 
19 no available; NAC, N-acetylcysteine; OR, odds ratio, vs., versus. 
20 a  2  represents between-study heterogeneity characterized by standard deviation. 
22 b the meta-regression based on empirical Bayes method was used to calculate ORs and 
23 95CIs. ORs are lower than 1 favor the former treatment of every comparison. 
24 
25 
26 Table S3: Evaluation of the model fit 
27 For a binomial likelihood each trial arm contributes 1 independent data point. 
29 Dbar is considered as an absolute measure of fit, and is used to check formally whether 
30 a model’s fit is satisfactory. This is the posterior mean of the deviance under the current 
31 
32 model minus the deviance for the saturated mode. We    can then compare the value of 
33 Dbar to the number of independent data points to check if the model fit can be improved. 
34 Leverage (PD) is considered an appropriate measure of the complexity of a model that 
35 
36 reasonably describes the data. PD also is termed the effective number of parameters, 
37 and is calculated as the posterior mean of the residual deviance minus the deviance  at 
38 the posterior mean of the fitted values. 
40 Deviance Information Criterion (DIC) is the sum of the posterior mean of the residual 
41 deviance and the PD  , and provides a measure of model fit that penalises model 
42 
43 complexity – lower values of the DIC suggest a more parsimonious model. The DIC is 
44 particularly useful for comparing different parameter models for the same   likelihood 
45 and data, for example fixed and random effects models or fixed effect models with and 
46 
47 without covariates. As shown in above table, the random consistency model is  clearly 
48 more parsimonious than the other three models. 
49 
50 
51 Table S4: Results of sensitivity analyses 
52 Data are odds ratio (95% CrI). All odds ratios use hydration as referenced agent. 
53 Heterogeneity was  assessed  using the  posterior  median  between  trial  variance,  τ2. 
55 Significant results are in bold. 
56 CM, contrast media; CrI, credible interval; DM, Diabetes mellitus; SUCRA,    surface 
57 
58 under the cumulative ranking curve measure; NAC, N-acetylcysteine. 
59 
60 
61 
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50 
Table S5: Results of meta-regression and subgroup analyses 
1 Data are odds ratio (95% CrI) after adjusting covariates: a. continuous variables include 
2 
3 “Mean CM dose”, “Baseline scr concentration”, and “Mean age years”; b.  categorical 
4 variables  include  “CM  type  (iso-,  low-  or  high-osmolar)”,  “Isotonic  (0.9%)     or 
5 hypotonic (0.45%) saline hydration”, “Different CI-AKI definitions (48h,72h or 120h)”, 
7 “Cardiovascular diagnostic/interventional procedures or enhanced CT or not specified 
8 radiologic procedure with CM”. All odds ratios use hydration as referenced agent. 
9 Heterogeneity was  assessed  using the  posterior  median  between  trial  variance,  τ2. 
11 Significant results are in bold. 
12 CM, contrast  media  CrI,  credible  interval;  CT, computed  tomography;  Scr, Serum 
13 
14 creatinine; NAC, N-acetylcysteine. 
15 
16 
Figure S1: Risk of bias summary: judgements from each study 
18 The green symbols represent low risk of bias, the yellow symbols represent unclear risk 
19 of bias, and the red symbols represent high risk of bias. The figure was generated using 
20 
21 Review Manager Version 5.0.16. 
22 
23 Figure S2: Risk of bias graph of included clinical trials 
24 
25 Each methodological quality item is presented as percentages across all included studies. 
26 The figure was generated using Review Manager Version 5.0.16. 
27 
28 
29 Figure S3: Cumulative and non-cumulative SUCRA ranking curves 
30 Treatment is ranked according to SUCRA. The SUCRA would be 1 when a  treatment 
31 
32 is certain to be the best and 0 when a treatment is certain to be the worst. Higher  rank 
33 indicates greater benefit probability of preventing CI-AKI. 
34 SUCRA, surface under the cumulative ranking curve measure; NAC, N-acetylcysteine. 
35 
36 
37 Figure S4: Assessment of inconsistency 
38 We estimated inconsistency as the difference between direct and indirect estimates 
40 (called inconsistency factor, IF) and the corresponding 95% confidence intervals  (CI) 
41 for IF in each closed loop. The following graphs show all closed triangular loops (loops 
42 
43 formed by three treatments) in CI-AKI outcome network. Inconsistent loops are those 
44 that present IF with 95% CIs incompatible with zero. 
45 There are two inconsistent loops (1–11–9 = Vitamins and its analogues –  Bicarbonate 
46 
47 sodium plus NAC – Hydration; 1–11–3 = Vitamins and its analogues – Bicarbonate 
48 sodium plus NAC – NAC) out of 13 loops. 
49 1 = Vitamins and its analogues, 2 = Natriuretic peptide, 3 = NAC, 4 = Prostaglandin, 5 
51 = High-dose statin, 6 = Low-dose statin, 7 = Theophylline, 8 = Bicarbonate sodium, 9 
52 = Hydration, 10 = Fenoldopam, 11 = Bicarbonate sodium plus NAC, 12 =   High-dose 
53 
54 statin plus NAC. 
55 
56 Item S1: Study protocol 
57 
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59 Item S3: Assessment domains of risk of bias 
60 
61 
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Table S1 Description of included studies 
 
 
Study 
 
Year 
Number 
of  
patients 
 
Men 
(%) 
 
Mean 
age 
 
CM 
 
Type of 
CM 
Mean 
volume of 
CM(mL) 
Inclusion 
criteria of 
kidney 
function 
 
Drug 1 
New 
cases of 
CI- 
AKI/total 
 
Drug 2 
New 
cases of 
CI- 
AKI/total 
 
Drug 3 
New 
cases of 
CI- 
AKI/total 
 
Drug 4 
New 
cases of 
CI- 
AKI/total 
 
Funding 
Source 
Gurkowski1 1995 125 98 63 
diatrizoate 
melamine 
high- 
osmolar 
100 Scr<2mg/dl 
misoprostol+ 
hydration 
1/63 
placebo+hy 
dration 
0/62     Non-industry 
Kurnik2 1998 247 83 60 NA NA 100 Scr>1.8mg/dl 
ANP+hydratio 
n 
44/187 
placebo+hy 
dration 
11/60     NA 
Abizaid3 1999 40 68 75 hexabrix 
low- 
osmolar 
190 Scr≥1.5mg/dl 
aminophylline 
+hydration 
6/20 hydration 7/20     NA 
Erley4 1999 64 78 64 iopromide 
low- 
osmolar 
114 Scr>1.5mg/dl 
theophylline+ 
hydration 
2/35 
placebo+hy 
dration 
1/29     NA 
 
Koch5 
 
2000 
 
117 
 
66 
 
67 
 
NA 
low- or 
iso- or 
high- 
osmolar 
 
159 
 
Scr>1.5mg/dl 
 
prostaglandin 
E1+hydration 
 
24/88 
 
placebo+hy 
dration 
 
15/29 
     
NA 
Tepel6 2000 83 57 66 iopromide 
low- 
osmolar 
75 Scr>1.2mg/dl 
NAC+hydrati 
on 
1/41 
placebo+hy 
dration 
9/42     NA 
 
Allapaband7 
 
2002 
 
123 
 
58 
 
71 
 
NA 
low- 
osmolar 
 
122 
 
Scr≥1.6mg/dl 
NAC+hydrati 
on 
 
8/45 
Fenoldopa 
m+hydratio 
n 
 
6/38 
placebo+ 
hydratio 
n 
 
6/40 
   
NA 
Briguori8 2002 183 86 64 iopromide 
low- 
osmolar 
124 Scr>1.2mg/dl 
NAC+hydrati 
on 
6/92 hydration 10/91     NA 
APART9 2002 54 80 73 ioxilan 
low- 
osmolar 
47 Scr≥1.4mg/dl 
NAC+hydrati 
on 
2/25 
placebo+hy 
dration 
13/29     NA 
Durham10 2002 79 66 70 Iohexol 
low- 
osmolar 
81 Scr≥1.7mg/dl 
NAC+hydrati 
on 
10/38 
placebo+hy 
dration 
9/41     NA 
Huber11 2002 100 9 NA iomeprol 
low- 
osmolar 
207 Scr>1.2mg/dl 
theophylline+ 
hydration 
2/50 
placebo+hy 
dration 
8/50     NA 
Kramer12 2002 56 75 60 NA 
low- 
osmolar 
NA Scr<1.3mg/dl 
theophylline+ 
hydration 
3/28 
placebo+hy 
dration 
4/28     Non-industry 
Shyu13 2002 121 68 70 iopamidol 
low- 
osmolar 
117 Scr 2-6mg/dl 
NAC+hydrati 
on 
2/60 
placebo+hy 
dration 
15/61     Non-industry 
 
Tumlin14 
 
2002 
 
45 
 
76 
 
63 
 
NA 
low- or 
iso- 
osmolar 
 
88 
 
Scr 2-5mg/dl 
fenoldopam+ 
hydration 
 
5/23 
placebo+hy 
dration 
 
9/22 
    Non-industry with 
drug supplied by 
industry 
RAPPID15 2003 80 88 69 iodixanol 
iso- 
osmolar 
229 
Scr>1.36mg/ 
dl 
NAC+hydrati 
on 
2/41 
placebo+hy 
dration 
8/39     Non-industry 
Boccalandr 
o16 
2003 179 60 66 iodixanol 
iso- 
osmolar 
192 Scr>1.2mg/dl 
NAC+hydrati 
on 
10/73 
placebo+hy 
dration 
13/106     NA 
Efrati17 2003 49 90 67 Iopromide 
low- 
osmolar 
140 Scr>1.2mg/dl 
NAC+hydrati 
on 
0/24 
placebo+hy 
dration 
2/25     Non-industry 
Mahmoud18 2003 120 NA NA NA NA NA 
Scr>1.36mg/ 
dl 
NAC+hydrati 
on 
3/60 
placebo+hy 
dration 
2/60     NA 
Huber19 2003 100 83 69 iomeprol 
low- 
osmolar 
207 Scr≥1.4mg/dl 
theophylline+ 
hydration 
2/50 
placebo+hy 
dration 
10/50     NA 
Kay20 2003 200 62 69 iopamidol 
low- 
osmolar 
125 Scr>1.2mg/dl 
NAC+hydrati 
on 
4/102 
placebo+hy 
dration 
12/98     Non-industry 
 
Kefer21 
 
2003 
 
104 
 
75 
 
63 
iopromide 
or iohexol 
low- 
osmolar 
 
199 
no limited 
kidney 
function 
NAC+hydrati 
on 
 
2/53 
placebo+hy 
dration 
 
3/51 
     
NA 
MacNeill22 2003 43 86 73 
iopromide 
or ioxilan 
low- 
osmolar 
110 Scr≥1.4mg/dl 
NAC+hydrati 
on 
1/21 
placebo+hy 
dration 
7/22     NA 
Oldemeyer2 
3 2003 96 55 76 iopamidol 
low- 
osmolar 
NA Scr>1.2mg/dl 
NAC+hydrati 
on 
4/49 
placebo+hy 
dration 
3/47     NA 
Stone24 2003 283 66 69 NA 
low- 
osmolar 
158 
CrCl<60ml/mi 
n 
fenoldopam+ 
hydration 
46/137 
placebo+hy 
dration 
44/146     Industry 
Agrawal25 2004 25 68 64 iohexol 
low- 
osmolar 
NA Scr≥1.5mg/dl 
NAC+hydrati 
on 
2/11 
placebo+hy 
dration 
2/14     NA 
Balderramo 
26 2004 61 NA NA NA NA NA CRF 
NAC+hydrati 
on 
1/33 
placebo+hy 
dration 
2/28     NA 
Briguori27 2004 192 85 69 iodixanol 
iso- 
osmolar 
164 Scr≥1.5mg/dl 
NAC+hydrati 
on 
4/97 
fenoldopan 
+hydration 
13/95     NA 
Fung28 2004 91 70 68 iopromide 
low- 
osmolar 
128 
Scr 1.7- 
4.5mg/dl 
NAC+hydrati 
on 
8/46 hydration 6/45     NA 
Goldenberg 
29 2004 80 83 70 iodamidol 
low- 
osmolar 
116 Scr≥1.5mg/dl 
NAC+hydrati 
on 
4/41 
placebo+hy 
dration 
3/39     NA 
Merten30 2004 119 45 68 iodamidol 
low- 
osmolar 
132 Scr≥1.1mg/dl 
NaHCO3+hyd 
ration 
1/60 hydration 8/59     Non-industry 
Miner31 2004 180 74 70 iohexol 
low- 
osmolar 
347 
Scr>1.2mg/dl 
or DM 
NAC+hydrati 
on 
9/95 
placebo+hy 
dration 
19/85     NA 
 
Ochoa32 
 
2004 
 
80 
 
58 
 
72 
iodixanol/i 
ohexol/iox 
aglate/diat 
rizoate 
low- or 
iso- or 
high- 
osmolar 
 
144 
Scr>1.8mg/dl 
(male) 
Scr>1.6mg/dl 
(female) 
 
NAC+hydrati 
on 
 
3/36 
 
placebo+hy 
dration 
 
11/44 
     
Non-industry 
Rashid33 2004 94 64 71 NA NA 143 Scr<1.3mg/dl 
NAC+hydrati 
on 
3/46 
placebo+hy 
dration 
3/48     No funding 
supported 
 
Spargias34 
 
2004 
 
231 
 
92 
 
66 
 
NA 
low- or 
iso- 
osmolar 
 
274 
 
Scr≥1.2mg/dl 
ascorbic 
acid+hydratio 
n 
 
11/118 
placebo+hy 
dration 
 
23/113 
     
NA 
Webb35 2004 447 61 70 ioversol 
low- 
osmolar 
120 
eGFR<50ml/ 
min 
NAC+hydrati 
on 
25/220 
placebo+hy 
dration 
24/227     Non-industry 
Azmus36 2005 397 NA NA NA NA NA Scr≥1.3mg/dl 
NAC+hydrati 
on 
14/196 
placebo+hy 
dration 
17/201     NA 
Gomes37 2005 156 59 65 ioxaglate 
low- 
osmolar 
103 Scr≥1.2mg/dl 
NAC+hydrati 
on 
8/77 
placebo+hy 
dration 
8/79     NA 
Gulel38 2005 50 76 61 ioxaglate 
low- 
osmolar 
NA Scr>1.3mg/dl 
NAC+hydrati 
on 
3/25 hydration 2/25     NA 
Kotlyar39 2005 60 83 67 iopromide 
low- 
osmolar 
87 Scr≥1.5mg/dl 
NAC+hydrati 
on 
0/41 
placebo+hy 
dration 
0/19     Non-industry with 
drug supplied by 
                 industry 
 
Coyle40 
 
2006 
 
134 
 
65 
 
65 
 
NA 
low- or 
iso- or 
high- 
osmolar 
 
93 
no limited 
kidney 
function 
 
NAC+hydrati 
on 
 
6/65 
 
hydration 
 
1/69 
     
NA 
Dussol41 2006 233 73 64 NA 
low- 
osmolar 
123 
CrCl 15- 
60ml/min 
theophylline+ 
hydration 
6/80 hydration 9/153     No funding 
supported 
Khalili42 2006 70 60 58 iohexol 
low- 
osmolar 
140 Scr≥1.2mg/dl 
NAC+hydrati 
on 
5/35 hydration 12/35     NA 
Marenzi43 2006 354 95 63 iohexol 
low- 
osmolar 
266 no dialysis 
NAC+hydrati 
on 
27/235 
placebo+hy 
dration 
39/119     Non-industry 
 
CAFCIN44 
 
2006 
 
84 
 
75 
 
68 
 
NA 
low- or 
iso- 
osmolar 
 
168 
 
Scr≥1.2mg/dl 
NAC+hydrati 
on 
 
5/44 
fenoldopan 
+hydration 
 
8/40 
     
NA 
 
Boscheri45 
 
2007 
 
143 
 
47 
 
71 
 
iodixanol 
iso- 
osmolar 
 
106 
 
Scr>1.4mg/dl 
ascorbic 
acid+hydratio 
n 
 
5/74 
placebo+hy 
dration 
 
3/69 
     
NA 
 
REMEDIAL 
46 
 
2007 
 
326 
 
90 
 
70 
 
iodixanol 
 
iso- 
osmolar 
 
174 
 
Scr 2-8mg/dl 
 
NAC+hydrati 
on 
 
12/111 
 
NAC+NaH 
CO3 
 
2/108 
ascorbic 
acid+NA 
C+hydrat 
ion 
 
12/107 
   
NA 
Carbonell47 2007 216 76 62 iopromide 
low- 
osmolar 
188 Scr<1.4mg/dl 
NAC+hydrati 
on 
11/107 
placebo+hy 
dration 
11/109     NA 
Hobikoglu48 2007 81 72 62 NA NA NA 
Scr 1.4- 
2mg/dl 
NAC+hydrati 
on 
2/40 
placebo+hy 
dration 
4/41     NA 
Hsu49 2007 20 NA NA iohexol 
low- 
osmolar 
NA Scr>1.6mg/dl 
NAC+hydrati 
on 
0/11 
placebo+hy 
dration 
5/9     NA 
Lawlor50 2007 78 69 NA NA NA 162 Scr>1.6mg/dl 
NAC+hydrati 
on 
4/53 
placebo+hy 
dration 
2/25     Non-industry 
Masuda51 2007 65 61 76 iopamidol 
low- 
osmolar 
116 Scr>1.1mg/dl 
NaHCO3+hyd 
ration 
2/30 
placebo+hy 
dration 
10/35     NA 
Ozcan52 2007 264 69 75 ioxaglate 
low- 
osmolar 
110 Scr>1.2mg/dl 
NAC+hydrati 
on 
11/88 NaHCO3 4/88 
hydratio 
n 
12/88   NA 
 
RENO53 
 
2007 
 
111 
 
69 
 
65 
 
iomeprol 
low- 
osmolar 
 
285 
no limited 
kidney 
function 
NAC+NaHCO 
3 
 
1/56 
NAC+hydra 
tion 
 
17/55 
     
NA 
DVD54 2007 229 75 67 iopromide 
low- 
osmolar 
134 
Scr 1.3- 
3.5mg/dl 
NAC+hydrati 
on 
6/114 hydration 7/115     Non-industry 
 
Rajamalar55 
 
2007 
 
40 
 
65 
 
76 
 
iohexol 
 
low- 
osmolar 
 
141 
Scr>1.4mg/dl 
(male) 
Scr>1.3mg/dl 
(female) 
 
NAC+hydrati 
on 
 
1/20 
 
placebo+hy 
dration 
 
2/20 
     
NA 
REINFORC 
E56 
2008 145 78 72 iodixanol 
iso- 
osmolar 
140 Scr>1.2mg/dl NaHCO3 3/71 hydration 2/74     NA 
Brar57 2008 323 36 71 ioxilan 
low- 
osmolar 
132 
eGFR<60ml/ 
min 
NaHCO3 30/165 hydration 26/158     Non-industry 
 
Heng58 
 
2008 
 
60 
 
78 
 
73 
iomeprol 
or   
iodixanol 
low- or 
iso- 
osmolar 
 
203 
eGFR<56ml/ 
min 
NAC+NaHCO 
3 
 
1/28 
 
NaHCO3 
 
2/32 
     
Non-industry 
Mohamed59 2008 100 84 57 iohexol 
low- 
osmolar 
132 
CrCl 40- 
90ml/min 
NAC+hydrati 
on 
2/49 
placebo+hy 
dration 
6/51     Non-industry 
 
PROMISS60 
 
2008 
 
236 
 
72 
 
66 
 
iodixanol 
iso- 
osmolar 
 
182 
 
Scr>1.1mg/dl 
simvastatin 
40mg+hydrati 
on 
 
3/118 
placebo+hy 
dration 
 
4/118 
     
Non-industry 
Kimmel61 2008 36 75 69 iomeprol 
low- 
osmolar 
193 Scr≥1.2mg/dl 
NAC+hydrati 
on 
2/17 
placebo+hy 
dration 
1/19     No funding 
supported 
Maioli62 2008 502 59 74 iodixanol 
iso- 
osmolar 
165 
CrCl<60ml/mi 
n 
NAC+hydrati 
on 
52/252 
NAC+NaH 
CO3 
38/250     NA 
Masuda63 2008 59 61 76 iopamidol 
low- 
osmolar 
116 Scr>1.1mg/dl NaHCO3 2/30 hydration 10/29     Non-industry 
Wang64 2008 46 59 67 iopromide 
low- 
osmolar 
93 no dialysis 
NAC+hydrati 
on 
0/23 hydration 0/23     NA 
 
Amini65 
 
2008 
 
90 
 
60 
 
64 
 
iohexol or 
iodixanol 
low- or 
iso- 
osmolar 
 
120 
Scr>1.5mg/dl 
(male) 
Scr>1.4mg/dl 
(female) 
 
NAC+hydrati 
on 
 
5/45 
 
placebo+hy 
dration 
 
6/45 
     
No funding 
supported 
Baskurt66 2009 145 60 68 ioversol 
low- 
osmolar 
120 
eGFR 30- 
60ml/min 
NAC+hydrati 
on 
5/72 
placebo+hy 
dration 
7/73     No funding 
supported 
Ferrario67 2009 200 65 75 iodixanol 
iso- 
osmolar 
174 
CrCl<55ml/mi 
n 
NAC+hydrati 
on 
8/99 
placebo+hy 
dration 
6/101     No funding 
supported 
Kim68 2009 108 NA NA iodixanol 
iso- 
osmolar 
NA 
CrCl<60ml/mi 
n 
ALA+hydratio 
n 
2/53 
placebo+hy 
dration 
2/55     NA 
 
NASPI69 
 
2009 
 
174 
 
78 
 
65 
 
iodixanol 
iso- 
osmolar 
 
210 
 
Scr≥1.1mg/dl 
NAC+hydrati 
on 
 
1/83 
ascorbic 
acid+hydrat 
ion 
 
4/91 
     
Non-industry 
Marikawa70 2009 254 72 74 iomeprol 
low- 
osmolar 
140 Scr≥1.3mg/dl 
ANP+hydratio 
n 
4/126 hydration 15/128     NA 
Pakfetrat71 2009 192 61 58 iodixanol 
iso- 
osmolar 
63 no dialysis NaHCO3 4/96 hydration 12/96     Non-industry 
 
Ratcliffe72 
 
2009 
 
78 
 
60 
 
66 
 
iodixanol 
 
iso- 
osmolar 
 
150 
Scr>1.5mg/dl 
(male) 
Scr>1.3mg/dl 
(female) 
 
hydration 
 
1/15 
 
NAC+hydra 
tion 
 
1/21 
 
NaHCO3 
 
2/19 
 
NAC+Na 
HCO3 
 
1/23 
 
NA 
 
Spargias73 
 
2009 
 
208 
 
89 
 
71 
 
NA 
low- or 
iso- 
osmolar 
 
203 
 
Scr≥1.4mg/dl 
iloprost+hydr 
ation 
 
8/103 
placebo+hy 
dration 
 
23/105 
     
Industry 
Tamura74 2009 144 88 73 iohexol 
low- 
osmolar 
85 
Scr 1.1- 
2mg/dl 
NaHCO3+hyd 
ration 
1/72 hydration 9/72     NA 
Tasanatong 
75 
 
2009 
 
103 
 
74 
 
67 
 
iopromide 
low- 
osmolar 
 
141 
 
Scr≥1.2mg/dl 
alpha 
tocopherol+h 
ydration 
 
12/52 
placebo+hy 
dration 
 
3/51 
     
NA 
Farahani76 2009 265 83 64 iohexol 
low- 
osmolar 
114 Scr≥1.5mg/dl 
NaHCO3+hyd 
ration 
8/130 hydration 11/135     Non-industry 
 
Jia77 
 
2009 
 
228 
 
36 
 
66 
iohexol or 
iodixanol 
low- or 
iso- 
osmolar 
 
NA 
 
no dialysis 
simvastatin 
20mg+hydrati 
on 
 
18/113 
simvastatin 
80mg+hydr 
ation 
 
6/115 
     
NA 
 
Zhou78 
 
2009 
 
100 
 
59 
 
60 
 
iopamidol 
low- 
osmolar 
 
116 
 
Scr<1.7mg/dl 
atorvastatin 
80mg+hydrati 
on 
 
0/50 
atorvastatin 
10mg+hydr 
ation 
 
3/50 
     
NA 
 
Hakan79 
 
2010 
 
60 
 
70 
 
61 
 
iobitridol 
low- 
osmolar 
 
NA 
no limited 
kidney 
function 
NAC+hydrati 
on 
 
1/30 
 
hydration 
 
1/30 
    No funding 
supported 
Carbonell80 2010 81 80 70 iopromide 
low- 
osmolar 
160 Scr≥1.4mg/dl 
NAC+hydrati 
on 
2/39 
placebo+hy 
dration 
10/42     NA 
Castini81 2010 156 88 72 iodixanol 
iso- 
osmolar 
195 Scr≥1.2mg/dl 
NAC+hydrati 
on 
9/53 NaHCO3 7/52 
hydratio 
n 
7/51   NA 
 
 
ENABLE82 
 
 
2010 
 
 
166 
 
 
73 
 
 
62 
iodixanol 
or   
iopamidol 
or   
iobitridol 
 
low- or 
iso- 
osmolar 
 
 
209 
Scr<1.4mg/dl 
(male) 
Scr<1.2mg/dl 
(female) 
 
NAC+hydrati 
on 
 
 
3/80 
 
 
hydration 
 
 
7/86 
     
 
NA 
Kinbara83 2010 45 62 70 iopamidol 
low- 
osmolar 
143 no dialysis 
NAC+hydrati 
on 
0/15 
aminophylli 
ne 
0/15 
hydratio 
n 
0/15   No funding 
supported 
Malhis84 2010 280 60 50 
iohexol or 
iopamidol 
low- 
osmolar 
141 no dialysis 
theophylline+ 
hydration 
2/128 NaHCO3 12/152     NA 
Matejka85 2010 56 61 75 iodixanol 
iso- 
osmolar 
95 Scr≥1.5mg/dl 
theophylline+ 
hydration 
3/31 
placebo+hy 
dration 
0/25     Non-industry 
 
Hakan86 
 
2010 
 
130 
 
41 
 
55 
 
iopamidol 
low- 
osmolar 
 
95 
 
Scr≤1.5mg/dl 
atorvastatin 
80mg+hydrati 
on+NAC 
 
2/60 
NAC+hydra 
tion 
 
7/70 
    No funding 
supported 
Rohani87 2010 60 NA 62 iohexol 
low- 
osmolar 
205 Scr>1.3mg/dl 
aminophylline 
+hydration 
4/30 
placebo+hy 
dration 
6/30     NA 
Sar88 2010 45 53 57 iohexol 
low- 
osmolar 
NA Scr<1.2mg/dl 
NAC+hydrati 
on 
0/25 hydration 2/20     No funding 
supported 
LIPSIA89 2010 249 68 68 iopromide 
low- 
osmolar 
170 no dialysis 
NAC+hydrati 
on 
18/126 
placebo+hy 
dration 
25/123     NA 
 
Toso90 
 
2010 
 
304 
 
64 
 
76 
 
iodixanol 
iso- 
osmolar 
 
158 
CrCl<60ml/mi 
n 
atorvastatin 
80mg+hydrati 
on+NAC 
 
15/152 
NAC+hydra 
tion 
 
16/152 
     
NA 
Farahani91 2010 72 79 62 iohexol 
low- 
osmolar 
118 Scr>1.5mg/dl 
NaHCO3+hyd 
ration 
2/36 hydration 2/36     Non-industry 
 
Zhang92 
 
2010 
 
149 
 
70 
 
64 
iohexol or 
iodixanol 
low- or 
iso- 
osmolar 
 
186 
no limited 
kidney 
function 
BNP+hydratio 
n 
 
12/74 
placebo+hy 
dration 
 
24/75 
     
Non-industry 
 
ACT93 
 
2010 
 
2272 
 
61 
 
68 
 
NA 
low- or 
iso- or 
high- 
osmolar 
 
100 
 
Scr>1.5mg/dl 
 
NAC+hydrati 
on 
 
147/1153 
 
placebo+hy 
dration 
 
142/1119 
     
Non-industry 
Kim94 2011 191 NA NA iodixanol 
iso- 
osmolar 
NA NA 
atorvastatin8 
0mg+hydratio 
5/92 hydration 4/99     NA 
         n         
PREVENT9 
5 2011 375 71 68 iodixanol 
iso- 
osmolar 
117 Scr≥1.1mg/dl 
NAC+hydrati 
on 
10/187 
NaHCO3+N 
AC 
17/188     Non-industry 
Maioli96 2011 300 74 65 iodixanol 
iso- 
osmolar 
216 no dialysis NaHCO3 18/150 hydration 34/150     No funding supported 
Motohiro97 2011 155 70 73 iopamidol 
low- 
osmolar 
135 
eGFR<60ml/ 
min 
NaHCO3+hyd 
ration 
2/78 hydration 10/77     NA 
 
ARMYDA98 
 
2011 
 
241 
 
78 
 
66 
 
iobitridol 
low- 
osmolar 
 
211 
 
Scr<3mg/dl 
atorvastatin8 
0mg+hydratio 
n 
 
6/120 
placebo+hy 
dration 
 
16/121 
     
NA 
Sadat99 2011 40 NA 72 iopamidol 
low- 
osmolar 
73 no dialysis 
NAC+hydrati 
on 
1/21 hydration 3/19     No funding 
supported 
Tanaka100 2011 76 82 62 iopamidol 
low- 
osmolar 
211 no dialysis 
NAC+hydrati 
on 
2/38 hydration 5/38     NA 
Ueda101 2011 59 78 76 
iopamidol 
or iohexol 
low- 
osmolar 
110 Scr≥1.1mg/dl NaHCO3 1/30 hydration 8/29     NA 
Aslanger102 2012 312 77 56 ioxaglate 
low- 
osmolar 
200 no dialysis 
NAC+hydrati 
on 
51/213 
placebo+hy 
dration 
23/99     No funding 
supported 
 
Bilasy103 
 
2012 
 
60 
 
60 
 
57 
 
iopamidol 
low- 
osmolar 
 
117 
 
no dialysis 
theophylline+ 
hydration+NA 
C 
 
0/30 
NAC+hydra 
tion 
 
6/30 
    No funding 
supported 
 
Cao104 
 
2012 
 
180 
 
57 
 
63 
 
NA 
 
NA 
 
161 
 
no dialysis 
atorvastatin4 
0mg+hydratio 
n 
 
6/90 
atorvastatin 
20mg+hydr 
ation 
 
18/90 
     
Non-industry 
Gomes105 2012 301 72 64 ioxaglate 
low- 
osmolar 
125 Scr≥1.1mg/dl NaHCO3 9/150 hydration 9/151     No funding supported 
Gunebakm 
az106 2012 80 68 66 iopromide 
low- 
osmolar 
63 Scr≥1.2mg/dl 
NAC+hydrati 
on 
9/40 hydration 11/40     No funding 
supported 
 
Hafiz107 
 
2012 
 
320 
 
57 
 
74 
iodixanol 
or    
iopamidol 
or ioversol 
low- or 
iso- 
osmolar 
 
105 
 
eGFR<50ml/ 
min 
 
hydration 
 
11/80 
 
NAC+hydra 
tion 
 
8/81 
 
NaHCO3 
 
6/79 
 
NaHCO3 
+NAC 
 
8/80 
 
No funding 
supported 
Jaffery108 2012 398 61 65 iodixanol 
iso- 
osmolar 
167 no dialysis 
NAC+hydrati 
on 
33/206 
placebo+hy 
dration 
25/192     No funding 
supported 
 
Kitzler109 
 
2012 
 
30 
 
57 
 
75 
 
iopromide 
 
low- 
osmolar 
 
NA 
Scr>1.3mg/dl 
(male) 
Scr>1.1mg/dl 
(female) 
 
NAC+hydrati 
on 
 
0/10 
vitamin 
E+hydratio 
n 
 
0/10 
placebo+ 
hydratio 
n 
0/10 
   
Non-industry 
 
Klima110 
 
2012 
 
258 
 
64 
 
77 
 
NA 
 
NA 
 
100 
Scr>1.3mg/dl 
(male) 
Scr>1.1mg/dl 
(female) 
 
NaHCO3 
 
16/169 
 
hydration 
 
1/89 
     
Non-industry 
CASIS111 2012 220 78 64 iohexol 
low- 
osmolar 
127 Scr≥1.1mg/dl 
NAC+hydrati 
on 
2/80 hydration 19/140     NA 
Li112 2012 161 76 66 iohexol 
low- 
osmolar 
102 
normal kidney 
function 
atorvastatin8 
0mg+hydratio 
2/78 
placebo+hy 
dration 
13/83     NA 
         n         
Okumura113 2012 112 68 74 iohexol 
low- 
osmolar 
66 
eGFR<60ml/ 
min 
carperitide+h 
ydration 
5/59 hydration 3/53     No funding 
supported 
 
NAPLE II114 
 
2012 
 
410 
 
54 
 
70 
 
iodixanol 
iso- 
osmolar 
 
181 
no limited 
kidney 
function 
atorvastatin8 
0mg+hydratio 
n+NAC 
 
7/202 
NaHCO3+N 
AC 
 
12/208 
     
Non-industry 
 
Zhou115 
 
2012 
 
156 
 
84 
 
71 
 
NA 
 
NA 
 
135 
 
Scr≥1.1mg/dl 
ascorbic 
acid+hydratio 
n 
 
6/82 
placebo+hy 
dration 
 
4/74 
    No funding 
supported 
 
Albabtain116 
 
2013 
 
185 
 
73 
 
61 
 
ioxaglate 
low- 
osmolar 
 
88 
 
Scr≥1.3mg/dl 
ascorbic 
acid+hydratio 
n 
 
2/57 
NAC+hydra 
tion 
 
5/62 
placebo+ 
hydratio 
n 
 
5/66 
   
NA 
Boucek117 2013 120 75 65 NA 
low- 
osmolar 
110 Scr≥1.1mg/dl NaHCO3 7/61 hydration 5/59     No funding supported 
 
Brueck118 
 
2013 
 
483 
 
64 
 
75 
 
iopromide 
low- 
osmolar 
 
112 
 
Scr≥1.3mg/dl 
ascorbic 
acid+hydratio 
n 
 
24/98 
NAC+hydra 
tion 
 
53/192 
placebo+ 
hydratio 
n 
 
62/193 
  No funding 
supported 
Cicek119 2013 78 60 65 iohexol 
low- 
osmolar 
78 Scr<1.5mg/dl 
ALA+hydratio 
n 
3/39 hydration 3/39     No funding 
supported 
 
Drorsak120 
 
2013 
 
81 
 
73 
 
71 
 
iopamidol 
low- 
osmolar 
 
138 
 
Scr≥1.2mg/dl 
ascorbic 
acid+hydratio 
n 
 
2/40 
placebo+hy 
dration 
 
3/41 
    No funding 
supported 
Ricardo121 2013 123 72 66 ioversol 
low- 
osmolar 
192 Scr≥1.2mg/dl NaHCO3 15/42 
NAC+NaH 
CO3 
3/43 
NAC+hy 
dration 
6/38   No funding 
supported 
Hui122 2013 182 NA NA NA NA NA NA 
NAC+hydrati 
on 
4/92 
placebo+hy 
dration 
10/90     NA 
 
 
ALIVE123 
 
 
2013 
 
 
202 
 
 
50 
 
 
72 
iodixanol 
or    
iopromide 
or    
iobitridol 
 
low- or 
iso- 
osmolar 
 
 
170 
 
CrCl≤60ml/mi 
n 
 
ALA+hydratio 
n 
 
 
3/100 
 
 
hydration 
 
 
7/102 
     
 
Non-industry 
Koc124 2013 195 52 62 NA NA 90 Scr<3mg/dl NaHCO3 15/94 hydration 6/101     NA 
 
Maaz125 
 
2013 
 
160 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
atorvastatin8 
0mg+NAC+h 
ydration 
 
2/80 
NAC+hydra 
tion 
 
9/80 
     
NA 
Miao126 2013 330 77 79 iohexol 
low- 
osmolar 
NA Scr<3mg/dl 
alprostadil+hy 
dration 
14/154 
placebo+hy 
dration 
39/176     Non-industry 
Poletti127 2013 110 50 78 iohexol 
low- 
osmolar 
118 
CrCl≤60ml/mi 
n 
NAC+hydrati 
on 
8/52 
placebo+hy 
dration 
10/58     NA 
Tasanarong 
128 2013 305 72 67 iopromide 
low- 
osmolar 
135 
eGFR≤60ml/ 
min 
tocopherol+h 
ydration 
11/204 
placebo+hy 
dration 
15/101     Non-industry 
 
Stephen129 
 
2013 
 
357 
 
41 
 
61 
iodixanol 
or    
iopamidol 
or ioversol 
low- or 
iso- 
osmolar 
 
123 
 
Scr>1.4mg/dl 
 
NAC+hydrati 
on 
 
14/185 
 
placebo+hy 
dration 
 
12/172 
     
Non-industry 
Erturk130 2014 307 64 66 iopromide 
low- 
osmolar 
126 
eGFR<60ml/ 
min 
NAC+hydrati 
on 
27/204 
placebo+hy 
dration 
7/103     No funding 
supported 
 
Han131 
 
2014 
 
2998 
 
39 
 
61 
 
iodixanol 
iso- 
osmolar 
 
115 
CKD stage 2- 
3 and DM 
rosuvastatin1 
0mg+hydratio 
n 
 
34/1498 
 
hydration 
 
58/1500 
     
NA 
 
Antonto132 
 
2014 
 
500 
 
61 
 
59 
ioxitalama 
te 
high- 
osmolar 
 
91 
no limited 
kidney 
function 
NAC+hydrati 
on 
 
49/126 
NaHCO3+h 
ydration 
 
75/125 
NaHCO3 
+NAC 
 
72/124 
 
hydration 
 
61/125 
 
Non-industry 
 
Kama133 
 
2014 
 
107 
 
55 
 
71 
 
iohexol 
low- 
osmolar 
 
NA 
no limited 
kidney 
function 
NAC+hydrati 
on 
 
7/36 
NaHCO3+h 
ydration 
 
4/36 
hydratio 
n 
 
5/35 
  No funding 
supported 
 
PRATO- 
ACS134 
 
2014 
 
504 
 
66 
 
66 
 
iodixanol 
 
iso- 
osmolar 
 
144 
 
no dialysis 
rosuvastatin2 
0-40mg 
+hydration+ 
NAC 
 
17/252 
 
NAC+hydra 
tion 
 
38/252 
     
Non-industry 
Li135 2014 163 67 64 iohexol 
low- 
osmolar 
170 
eGFR≥30ml/ 
min 
Prostaglandin 
E1+hydration 
3/82 hydration 9/81     Non-industry 
Manari136 2014 592 75 65 iodixanol 
iso- 
osmolar 
198 no dialysis NaHCO3 56/293 hydration 51/299     NA 
PROMEC13 
7 2014 231 55 60 iohexol 
low- 
osmolar 
100 Scr>1.2mg/dl NaHCO3 12/111 hydration 8/120     No funding supported 
Thayssen13 
8 
 
2014 
 
715 
 
77 
 
63 
 
iodixanol 
iso- 
osmolar 
 
140 
 
no dialysis 
 
hydration 
 
43/181 
NAC+hydra 
tion 
 
32/176 
NaHCO3 
+hydrati 
on 
 
33/181 
NaHCO3 
+NAC 
 
33/177 
 
Non-industry 
Yang139 2014 527 45 59 iohexol 
low- 
osmolar 
127 
eGFR≥30ml/ 
min 
hydration 5/161 
NAC+hydra 
tion 
7/157 NaHCO3 8/159 
NaHCO3 
+NAC 
8/150 
No funding 
supported 
 
Fahmy140 
 
2014 
 
200 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
Rosuvastatin 
20mg+hydrati 
on 
 
15/100 
placebo+hy 
dration 
 
38/100 
     
NA 
Yeganehkh 
ah141 
2014 78 78 59 iohexol 
low- 
osmolar 
44 Scr≤4mg/dl 
NaHCO3+hy 
dration 
7/50 
NAC+hydra 
tion 
6/50 
hydratio 
n 
7/50   Non-industry 
 
Abaci142 
 
2015 
 
208 
 
71 
 
68 
 
ioversol 
low- 
osmolar 
 
129 
eGFR 30- 
60ml/min 
Rosuvastatin 
40mg+hydrati 
on 
 
6/103 
 
hydration 
 
9/105 
    No funding 
supported 
Arabmome 
ni143 2015 62 43 62 iodixanol 
low- 
osmolar 
136 
normal kidney 
function 
theophylline+ 
hydration 
6/30 
NAC+hydra 
tion 
7/32     Non-industry 
 
Bidram144 
 
2015 
 
200 
 
91 
 
60 
 
iodixanol 
iso- 
osmolar 
 
35 
eGFR≥60ml/ 
min 
atorvastatin 
80mg+hydrati 
on 
 
1/100 
placebo+hy 
dration 
 
2/100 
     
NA 
 
CONTRAS 
T145 
 
 
2015 
 
 
453 
 
 
76 
 
 
68 
iohexol or 
iopamidol 
or ioversol 
or    
iopromide 
 
low- 
osmolar 
 
 
116 
 
eGFR 15- 
60ml/min 
 
NAC+hydrati 
on 
 
 
10/153 
 
 
NaHCO3 
 
 
19/149 
 
NAC+Na 
HCO3 
 
 
16/151 
   
No funding 
supported 
 
Galal146 
 
2015 
 
80 
 
64 
 
56 
 
NA 
low- 
osmolar 
 
241 
eGFR 60- 
90ml/min 
Atorvastatin8 
0mg+hydratio 
n 
 
5/40 
Atorvastati 
n10mg+hy 
dration 
 
7/40 
    No funding 
supported 
 
Jo147 
 
2015 
 
218 
 
85 
 
59 
 
NA 
 
NA 
 
NA 
no limited 
kidney 
function 
Atorvastatin8 
0mg+hydratio 
n 
 
6/110 
Atorvastati 
n10mg+hy 
dration 
 
11/108 
     
Non-industry 
 
Shehata148 
 
2015 
 
130 
 
62 
 
56 
 
iopromide 
low- 
osmolar 
 
276 
eGFR 30- 
90ml/min 
atorvastatin 
80mg+hydrati 
on+NAC 
 
5/65 
NAC+hydra 
tion 
 
13/65 
    No funding 
supported 
BOSS149 2015 391 58 72 NA NA 107 
eGFR<45ml/ 
min 
NaHCO3 26/195 hydration 18/196     Non-industry 
Rezaei150 2016 298 69 67 iodixanol 
low- 
osmolar 
50 
eGFR<60ml/ 
min 
Vitamin 
E+hydration 
10/149 
placebo+hy 
dration 
21/149     Non-industry 
 
ALA, alpha-lipoic acid; ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CI-AKI, contrast-induced acute kidney injury; Crcl, Creatinine 
clearance rate; eGFR, estimated glomerular filtration rate; NA, no available; NAC, N-acetylcysteine; NaHCO3, bicarbonate sodium; Scr, Serum creatinine. 
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Table S2. Meta-analytic results of traditional pairwise meta-analysis 
 
 
Comparisons 
 
N 
 
n 
 
2a 
 
I2% (95%CI) 
 
Q 
OR (95%CI)b from 
traditional pairwise 
meta-analysis 
Vitamins and its analogues 
vs. hydration 
 
13 
 
2149 
 
0 
 
0(0,58) 
 
10.19 
 
0.49(0.33,0.70) 
Vitamins and its analogues 
vs. NAC 
 
5 
 
821 
 
0 
 
0(0,85) 
 
2.58 
 
0.80(0.17,2.29) 
Vitamins and its analogues 
vs. bicarbonate sodium+NAC 
 
1 
 
215 
 
NA 
 
NA 
 
NA 
 
6.70(1.46,30.68) 
Natriuretic peptide vs. 
hydration 
 
4 
 
762 
 
0.5 
 
68(6,89) 
 
9.3 
 
0.60(0.07,4.78) 
NAC vs. theophylline 3 152 0.67 29(0,93) 2.83 1.05(0.003,252) 
NAC vs. bicarbonate sodium 11 1959 0.26 53(8,76) 21.45 0.77(0.47,1.22) 
NAC vs. hydration 70 12128 0.17 36(14,52) 104.68 0.74(0.62,0.88) 
NAC vs. fenoldopam 2 276 0 0c 0.55 0.32(0.006,147.8) 
NAC vs. bicarbonate 
sodium+NAC 
 
12 
 
2792 
 
0.63 
 
65(35,81) 
 
31.53 
 
1.19(0.61,2.14) 
NAC vs. high-dose 
statin+NAC 
 
6 
 
1228 
 
0.06 
 
23(0,68) 
 
5.21 
 
2.57(0.94,4.87) 
Prostaglandin vs. hydration 5 943 0 0(0,79) 1.87 0.35(0.17,0.65) 
High-dose statin vs. low-dose 
statin 
 
5 
 
806 
 
0 
 
0(0,79) 
 
2.21 
 
0.69(0.08,0.78) 
High-dose statin vs. hydration 7 1437 0.1 21(0,64) 7.59 0.38(0.18,0.71) 
Low-dose statin vs. hydration 1 2998 NA NA NA 0.58(0.38,0.89) 
Theophylline vs. bicarbonate 
sodium 
 
1 
 
280 
 
NA 
 
NA 
 
NA 
 
0.19(0.04,0.85) 
Theophylline vs. hydration 9 739 0.39 32(0,69) 11.73 0.55(0.18,1.21) 
Bicarbonate sodium vs. 
hydration 
 
28 
 
5561 
 
0.66 
 
60(40,74) 
 
68.35 
 
0.68(0.46,0.95) 
Bicarbonate sodium vs. 
bicarbonate sodium+NAC 
 
8 
 
1598 
 
0.13 
 
25(0,66) 
 
9.28 
 
1.21(0.70,2.04) 
Fenoldopam vs. hydration 2 328 0.32 55c 2.26 0.76(0.009,516.7) 
Bicarbonate sodium+ NAC 
vs. hydration 
 
6 
 
1194 
 
0.06 
 
1(0,75) 
 
5.07 
 
1.21(0.70,2.04) 
High-dose statin+NAC vs. 
bicarbonate sodium+NAC 
 
1 
 
410 
 
NA 
 
NA 
 
NA 
 
0.45(0.20,1.23) 
Abbreviations: CI, confidence interval; N, number of trials; n, number of patients; NA, no available; NAC, N- 
acetylcysteine; OR, odds ratio, vs., versus. 
a  2  represents between-study heterogeneity characterized by standard deviation. 
b the meta-regression based on empirical Bayes method was used to caculate ORs and 95CIs. ORs are lower 
than 1 favor the former treatment of every comparison. 
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Table S3. Evaluation of the model fit 
 
 
Model assumption 
 
Dbar 
 
Pd 
 
# of data points 
 
DIC 
Random consistency 338 232 322 570 
Random inconsistency 343 236 322 579 
Fixed consistency 629 156 322 785 
Fixed inconsistency 502 168 322 630 
For a binomial likelihood each trial arm contributes 1 independent data point. 
 
Dbar is considered as an absolute measure of fit, and is used to check formally whether a model’s 
fit is satisfactory. This is the posterior mean of the deviance under the current model minus the 
deviance for the saturated mode. We can then compare the value of Dbar to the number of 
independent data points to check if the model fit can be improved. 
Leverage (PD) is considered an appropriate measure of the complexity of a model that reasonably 
describes the data. PD also is termed the effective number of parameters, and is calculated as the 
posterior mean of the residual deviance minus the deviance at the posterior mean of the fitted values. 
Deviance Information Criterion (DIC) is the sum of the posterior mean of the residual deviance 
and the PD , and provides a measure of model fit that penalises model complexity – lower values of 
the DIC suggest a more parsimonious model. The DIC is particularly useful for comparing different 
parameter models for the same likelihood and data, for example fixed and random effects models 
or fixed effect models with and without covariates. As shown in above table, the random consistency 
model is clearly more parsimonious than the other three models. 
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Table S4. Results of sensitivity analyses 
 
 
 
Treatment strategies 
 
Standard 
analysis 
Excluding 13 
trials with 
sample size less 
than 50 
Excluding 18 trials 
with high-osmolar 
and unspecified CM 
type 
Excluding 14 
trials with oral 
hydration and 
unspecified 
hydration agent 
Excluding 9 
trials evaluated 
only patients 
with normal 
kidney function 
 
Excluding 
data for non- 
DM patients 
 
Excluding 24 
trials published 
before 2004 
High-dose statin+NAC 0.31(0.14,0.60) 0.32(0.15,0.58) 0.32(0.14,0.64) 0.38(0.15,0.83) 0.32(0.14,0.66) 0.24(0.07,1.27) 0.33(0.16,0.60) 
High-dose statin 0.37(0.19,0.64) 0.38(0.21,0.64) 0.39(0.21,0.68) 0.35(0.17,0.62) 0.42(0.20,0.72) 0.47(0.11,1.33) 0.38(0.21,0.62) 
Prostaglandin 0.37(0.17,0.72) 0.37(0.17,0.68) 0.43(0.16,0.86) 0.40(0.17,0.74) 0.45(0.21,0.87) - 0.42(0.16,0.88) 
Theophylline 0.48(0.26,0.82) 0.46(0.24,0.82) 0.46(0.26,0.75) 0.55(0.29,0.93) 0.48(0.23,0.85) 0.77(0.01,4.69) 0.60(0.27,1.14) 
Bicarbonate sodium+NAC 0.62(0.40,0.88) 0.57(0.38,0.80) 0.47(0.30,0.69) 0.54(0.36,0.77) 0.55(0.37,0.79) 1.14(0.46,2.42) 0.56(0.37,0.82) 
Vitamins and its analogues 0.64(0.41,0.95) 0.64(0.42,0.96) 0.58(0.38,0.87) 0.63(0.41,0.95) 0.62(0.38,0.93) 0.87(0.43,1.57) 0.75(0.48,1.13) 
NAC 0.67(0.54,0.81) 0.71(0.58,0.87) 0.64(0.52,0.77) 0.67(0.54,0.81) 0.66(0.54,0.81) 0.81(0.54,1.14) 0.73(0.59,0.88) 
Natriuretic peptide 0.69(0.31,1.37) 0.71(0.31,1.40) 0.70(0.32,1.34) 0.71(0.30,1.31) 0.71(0.31,1.35) 1.91(0.45,5.71) 0.62(0.27,1.30) 
Fenoldopam 0.70(0.32,1.36) 1.69(0.68,3.44) 1.22(0.54,2.48) 1.26(0.57,2.44) 1.26(0.55,2.52) 0.95(0.41,1.85) 2.53(0.69,7.05) 
Bicarbonate sodium 0.78(0.59,1.01) 0.79(0.60,1.00) 0.66(0.49,0.84) 0.77(0.58,0.99) 0.78(0.59,1.01) 1.31(0.67,2.38) 0.78(0.59,0.99) 
Low-dose statin 0.98(0.41,2.07) 0.96(0.44,1.90) 0.89(0.39,1.72) 0.74(0.30,1.52) 1.04(0.41,2.11) 0.65(0.20,1.52) 0.95(0.42,1.85) 
Hydration Reference Reference Reference Reference Reference Reference Reference 
Heterogeneity 0.33(0.21,0.54) 0.35(0.19,0.56) 0.30(0.16,0.49) 0.34(0.19,0.55) 0.35(0.19,0.54) 0.15(0.00,0.71) 0.29(0.15,0.50) 
DIC 570 521 500 522 541 142 480 
Number of trials 150 137 132 125 141 38 126 
Heterogeneity change  rise 6% drop 9% rise 3% rise 6% drop 55% drop 12% 
Data are odds ratio (95% CrI). All odds ratios use hydration as referenced agent. Heterogeneity was assessed using the posterior median between trial variance, 
τ2. Significant results are in bold. CM, contrast media; CrI, credible interval; DM, Diabetes mellitus; SUCRA, surface under the cumulative ranking curve measure; 
NAC, N-acetylcysteine; 
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Table S5. Results of meta-regression and subgroup analyses 
 
Treatment 
strategies 
 
Standard 
analysis 
 
Mean CM 
dose 
 
Baseline Scr 
concentration 
 
Mean age 
years 
 
CM type (iso-, 
low- or high- 
osmolar) 
Isotonic 
(0.9%) or 
hypotonic 
(0.45%) saline 
hydration 
Different CI- 
AKI 
definitions(48h 
,72h or 120h) 
Cardiovascular diagnostic/ 
interventional procedures 
or enhanced CT or not 
specified radiologic 
procedure with CM 
High-dose 
statin+NAC 
0.31(0.14,0.60) 0.35(0.14,0.69) 0.29(0.13,0.55) 0.35(0.15,0.72) 0.33(0.14,0.65) 0.40(0.15,0.86) 0.33(0.14,0.66) 0.29(0.13,0.54) 
High-dose 
statin 
0.37(0.19,0.64) 0.36(0.15.0.76) 0.34(0.16,0.64) 0.35(0.17,0.68) 0.44(0.21,0.80) 0.39(0.17,0.75) 0.36(0.17,0.68) 0.33(0.17,0.58) 
Prostaglandin 0.37(0.17,0.72) 0.40(0.14,0.89) 0.38(0.17,0.74) 0.37(0.17,0.76) 0.37(0.14,0.70) 0.43(0.19,0.82) 0.35(0.15,0.68) 0.47(0.20,0.92) 
Theophylline 0.48(0.26,0.82) 0.46(0.24,0.84) 0.47(0.25,0.79) 0.52(0.28,0.90) 0.48(0.25,0.84) 0.59(0.31,0.99) 0.45(0.24,0.77) 0.46(0.25,0.77) 
Bicarbonate 
sodium+NAC 
0.62(0.40,0.88) 0.54(0.35,0.80) 0.51(0.33,0.73) 0.55(0.37,0.79) 0.52(0.34,0.75) 0.57(0.36,0.84) 0.45(0.29,0.69) 0.52(0.34,0.75) 
Vitamins and 
its analogues 
0.64(0.41,0.95) 0.62(0.39,0.97) 0.63(0.39,0.96) 0.57(0.32,0.90) 0.88(0.41,1.67) 0.66(0.43,0.97) 0.70(0.45,1.03) 0.72(0.48,1.02) 
NAC 0.67(0.54,0.81) 0.66(0.52,0.81) 0.66(0.52,0.82) 0.67(0.54,0.83) 0.65(0.53,0.79) 0.70(0.56,0.89) 0.67(0.53,0.82) 0.64(0.51,0.77) 
Natriuretic 
peptide 
0.69(0.31,1.37) 0.71(0.30,1.40) 0.71(0.31,1.35) 0.71(0.33,1.42) 0.70(0.30,1.45) 0.75(0.33,1.51) 0.91(0.33,1.88) 0.66(0.30,1.27) 
Fenoldopam 0.70(0.32,1.36) 1.25(0.47,2.47) 1.25(0.54,2.47) 1.27(0.56,2.49) 1.25(0.53,2.39) 1.43(0.57,2.94) 1.21(0.52,2.35) 1.18(0.52,2.35) 
Bicarbonate 
sodium 
0.78(0.59,1.01) 0.78(0.59,1.02) 0.77(0.58,0.99) 0.78(0.60,1.01) 0.67(0.49,0.88) 0.79(0.59,1.04) 0.75(0.55,1.04) 0.74(0.55,0.96) 
Low-dose 
statin 
0.98(0.41,2.07) 0.92(0.33,2.10) 0.91(0.37,1.92) 0.94(0.32,2.18) 1.00(0.38,2.50) 0.79(0.31,1.65) 0.91(0.36,1.90) 0.83(0.34,1.68) 
Hydration Reference Reference Reference Reference Reference Reference Reference Reference 
Heterogeneity 0.33(0.21,0.54) 0.38(0.21,0.60) 0.34(0.19,0.56) 0.33(0.19,0.54) 0.30(0.18,0.52) 0.33(0.20,0.55) 0.33(0.19,0.58) 0.33(0.20,0.55) 
B coefficient 
 0.001(- 
0.008,0.007) 
-0.27(- 
2.04,1.48) 
-0.05(- 
0.17,0.07) 
0.45(- 
0.21,1.18) 
-0.21(- 
0.58,0.19) 
0.09(- 
0.19,0.35) 
0.09(-0.10,0.28) 
DIC 570 502 534 530 519 517 501 571 
Heterogeneity 
change 
 rise 15% rise 3% 0% drop 9% 0% 0% 0% 
Data are odds ratio (95% CrI) after adjusting covariates: a. continuous variables include “Mean CM dose”, “Baseline scr concentration”, and “Mean age years”; 
b. categorical variables include “CM type (iso-, low- or high-osmolar)”, “Isotonic (0.9%) or hypotonic (0.45%) saline hydration”, “Different CI-AKI definitions 
(48h,72h or 120h)”, “Cardiovascular diagnostic/interventional procedures or enhanced CT or not specified radiologic procedure with CM”. All odds ratios   use 
hydration as referenced agent. Heterogeneity was assessed using the posterior median between trial variance, τ2. Significant results are in bold. CM, contrast 
media CrI, credible interval; CT, computed tomography; Scr, Serum creatinine; NAC, N-acetylcysteine. 
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Item S1.    Study protocol: 
 
PROTOCOL First drafted in October 2014 
Modified in January 2015 
 
 
 
 
 
 
 
 
 
 
 
Comparative Effectiveness of 12 Treatment Strategies in Preventing 
Contrast-Induced Acute Kidney Injury: A Systematic Review and 
Bayesian Network Meta-analysis 
 
 
 
 
 
 
Xiaole Su, Xinfang Xie, Lijun Liu, Jicheng Lv, Fujian Song, Perkovic Vlado and Hong 
Zhang 
Objectives: 
 
Integrate the available evidence to compare various types of pharmacological strategies 
when used in patients undergoing diagnostic and/or interventional procedures with 
contrast media(CM) and create hierarchies of the comparative efficacy of active drug 
treatments on preventing contrast-induced acute kidney injury (CI-AKI). 
Background 
 
Acute injure in renal function induced by CM is generally mild and transient but can 
result in lasting renal dysfunction and the need for renal replacement therapy. CI-AKI 
is a leading cause of new onset kidney injury in hospitalized patients (1, 2). It is 
associated with significantly increased in-hospital morbidity and mortality, acceleration 
of chronic kidney disease, and increased costs of medical care (3). There have been a 
large number of pharmacological strategies to prevent CI-AKI so far, such as N- 
acetylcysteine (NAC), theophylline, fenoldopam, dopamine, iloprost, statins, 
bicarbonate sodium, ascorbic acid (vitamin C), vitamin E and. The question of which 
treatment strategies should be preferred for the prevention of CI-AKI is controversial, 
and traditional meta-analyses are hindered by heterogeneity across trials and the lack 
of trials direct comparing different treatment agents. We will undertake a network meta- 
analysis, which accounts for both direct and indirect comparisons to assess the efficacy 
of treatments on preventing CI-AKI. 
Research Plan: 
 
A) Methods of the Review 
 
We will conduct a Bayesian-framework, multiple-treatments meta-analysis (which uses 
both direct and indirect comparisons) of randomized controlled trials (RCTs) (4). 
 
B) Data Sources: 
 
Relevant RCTs will be identified by computerized searches from the following data 
sources without language restriction: 
1) MEDLINE OVID SP (from 1947 through October 2014); 
 
2) EMBASE (from 1966 through October 2014); 
 
3) The Cochrane Central Register of Controlled Trials (no date restriction); 
 
4) Reference lists in nephrology textbooks, review articles, and relevant trials were 
also searched. 
C) Study Selection: 
 
Types of Studies: 
 
· Inclusion criteria: 
 
We will include RCTs compared two or more of treatment groups received: NAC, 
theophylline (aminophylline), fenoldopam, iloprost, alprostadil, prostaglandin E1, 
statins, statins plus NAC, bicarbonate sodium, bicarbonate sodium plus NAC, ascorbic 
acid, vitamin E, tocopherol, alpha-lipoic acid, atrial natriuretic peptide, B-type 
natriuretic peptide, carperitide and hydration or placebo plus hydration. All above 
active drug treatments were based on hydration. All participants underwent diagnostic 
and/or interventional procedures with CM. 
· Exclusion criteria: 
 
Trials contained only one or none of the above strategies. 
 
Types of Participants: 
· Inclusion criteria: 
 
Adult patients (age≥18 years) underwent diagnostic and/or interventional procedures 
with CM. 
· Exclusion criteria: None 
 
Type of Intervention: 
 
· Treatment groups: 
 
N-acetylcysteine, theophylline (aminophylline), fenoldopam, iloprost, alprostadil, 
prostaglandin E1, statins, statins plus NAC, bicarbonate sodium, bicarbonate sodium 
plus NAC, ascorbic acid, vitamin E or its analogues (tocopherol), alpha-lipoic acid, 
atrial natriuretic peptide, B-type natriuretic peptide, carperitide and hydration or 
placebo plus hydration; 
· Compared two or more of the above mentioned treatment agents; 
 
· All above active drug treatments were based on hydration. 
 
Type of Outcome Measures: 
 
· Primary Outcome 
 
The occurrence of CI-AKI, defined as an absolute increase in baseline serum 
creatinine greater than 44.2 μmol/L (0.5 mg/dL) or a relative increase greater than 25% 
within typically 48-72 h after contrast injection. If 48-72 h data were not available, we 
used data within 5 days (the data point closest to 48-72 h was given preference). 
· Secondary Outcome 
 
None 
 
D) Assess Study Quality: 
We will use the Cochrane risk of bias method to appraise study quality on the seven 
domains (low, unclear, or high bias for sequence generation; allocation concealment; 
blinding of participants, personnel and outcome assessors; incomplete outcome data; 
selective outcome reporting; and other sources of bias) (5). 
E) Statistical analysis 
 
We will use Stata 12.0 to perform the traditional pairwise meta-analysis. Bayesian 
network meta-analysis will be done with WinBUGS version 1.4.3 and the R2WinBUGS 
package of R software 3.1.1. Clinical outcome analyses were compared by odds ratios 
(ORs) and 95% credible intervals (CrIs) using a Bayesian hierarchical random-effects 
model. Model fit will be assessed by comparing deviance information criterion (DIC). 
We will use the surface under the cumulative ranking (SUCRA) probabilities to rank 
the treatments (6). We will estimate the absolute difference between direct and indirect 
estimates in each closed loop. A significant (95% CrI that excludes 0) disagreement 
between direct and indirect evidence will indicate Inconsistent loops (7,8). 
We will do multiple-treatments meta-regression with the following covariates: mean 
age, mean CM dose, and baseline serum creatinine concentration (7). Subgroup 
analyses will be performed by comparing with trials using with different CI-AKI 
definitions, and comparing with trials of cardiovascular diagnostic/interventional 
procedures and CT examination (7). Sensitivity analyses will be conducted by only 
including of trials of DM patients and by excluding of trials with small sample size and 
trails of high-osmolar CM used. 
F) The Search Strategy: 
1) MEDLINE OVID SP 
 
1. exp Acute Kidney Injury/ 
 
2. exp renal failure/ 
 
3. (kidney disease* or renal disease* or renal failure or kidney failure or acute kidney 
or acute renal or nephrotoxic or nephropathy).mp. 
4. (impair or injury or damage or reduce).mp. and (renal or kidney).mp. 
 
5. 1 or 2 or 3 or 4 
 
6. (contrast-induced or contrast-associated).mp. 
 
7. (contrast or radiocontrast or iopamidol or iodine or ioxaglic acid or iodine 
compounds) .mp. 
8. (iohexol or urography or tomography or X ray computed or diatrizoate).mp. 
 
9. 6 or 7 or 8 
 
10. randomized controlled trial .pt. 
 
11. controlled clinical trial.pt. 
 
12. randomized.ab. 
 
13. placebo. ab. 
 
14. clinical trials as topic.sh 
 
15. randomly.ab. 
 
16. trial.ti. 
 
17. 10 or 11 or 12 or 13 or 14 or 15 or 16 
 
18. animals.sh. not (humans.sh. and animals.sh.) 
 
19. 17 not 18 
20. 5 and 9 and 19 
 
 
 
2) EMBASE 
 
#1   ' Acute Kidney Injury'/exp 
 
#2   ' renal failure'/exp 
 
#3 ‘kidney disease$’ or ‘renal disease$’ or ‘renal failure’ or ‘kidney failure’ or 
‘acute kidney’ or ‘acute renal’ or nephrotoxic or nephropathy 
#4   (impair or injury or damage or reduce) and (renal or kidney) 
 
#5   #1 OR #2 OR #3 OR #4 
 
#6   ‘contrast-induced’ or ‘contrast-associated’ 
 
#7 contrast or radiocontrast or iopamidol or iodine or ‘ioxaglic acid’ or ‘iodine 
compound$’ 
#8 iohexol or urography or tomography or ‘X ray computed’ or diatrizoate 
 
#9   #6 OR #7 OR #8 
 
#10 random$ OR blind$ OR placebo OR 'meta analysis' 
 
#11 #5 AND #9 AND #10 
 
 
 
3) CENTRAL 
 
#1   MeSH descriptor: [Acute Kidney Injury] explode all trees 
 
#2   MeSH descriptor: [renal failure] explode all trees 
 
#3 kidney disease* or renal disease* or renal failure or kidney failure or acute kidney 
or acute renal or nephrotoxic or nephropathy 
#4   (impair or injury or damage or reduce) and (renal or kidney) 
 
#5   #1 or #2 or #3 or #4 
 
#6   contrast-induced or contrast-associated 
 
#7 contrast or radiocontrast or iopamidol or iodine or ioxaglic acid or iodine 
compound* 
#8   iohexol or urography or tomography or X ray computed or diatrizoate 
 
#9   #6 or #7 or #8 
 
#10 #5 and #9 
 
4) Reference lists of nephrology textbooks, review articles, and relevant trials were 
also searched. 
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Item S2. Assessment domains of risk of bias 
 
We assessed risk of bias for sequence generation, allocation concealment, blinding, 
selective reporting, incomplete outcome data and other sources of bias, and determined 
overall risk of bias based on predefined rules, utilizing the Cochrane Collaboration risk 
of bias tool.1 
Sequence generation    (Selection bias) 
 
• Low risk of bias, if randomization was generated by a computer, or a table of random 
numbers. 
• High risk of bias, if method of randomization was inadequate (i.e. "quasi- 
randomized"). 
• Unclear risk of bias, if method of randomization was not described. 
 
Allocation concealment (Selection bias) 
 
• Low risk of bias, if the method of allocation involved a central independent unit or 
consecutively numbered sealed envelopes. 
• High risk of bias, if allocation sequence was known to the investigators or conducted 
with an inadequate method. 
• Unclear risk of bias, if the method of allocation concealment was not described. 
 
Blinding of participants and personnel (Performance bias) 
 
• Low risk of bias, if the study was of a double-blind design. 
 
• High risk of bias, if the study was open-label. 
 
• Unclear risk of bias, if there was insufficient information to determine whether the 
study was double-blind or open-label. 
Blinding of outcome assessment (Detection bias) 
 
• Low risk of bias, if the outcome assessment was blind. 
 
• High risk of bias, if the outcome assessment was open. 
 
• Unclear risk of bias, if there was insufficient information to determine whether the 
outcome assessment was blind or open. 
Selective outcome reporting (Detection bias) 
 
• Low risk of bias, if the specific outcome was reported adequately for all treatment 
arms. 
• High risk of bias, if the specific outcome was reported with inadequate detail for the 
data to be included in a meta-analysis or if it was reported only for a subset of the 
randomized population. 
• Unclear risk of bias, if there was insufficient information to assess whether the risk of 
bias of selective outcome reporting was present. 
Incomplete outcome data (Attrition bias) 
 
• Low risk of bias, if 
 
1. attrition rate was balanced between treatment arms and relatively low (below 20%), 
and 
2. reasons for discontinuation were described, and 
 
3. an intention-to-treat analysis was performed, and 
 
4. an appropriate method of imputation of missing outcome data was applied. 
 
• High risk of bias, if 
 
1. withdrawal rates were unbalanced between treatment arms or more than 20%, or 
2. reasons for drop-outs were not clearly described, or 
 
3. an inappropriate analysis was performed (i.e. per protocol analysis), or 
 
4. an inappropriate imputation method (i.e. last observation carried forward method) 
was used to handle missing data. 
• Unclear risk of bias, if it is not clear whether there were any drop-outs, or reasons for 
these withdrawals are not clear, or no method of imputation of missing data is 
mentioned. 
Pharmaceutical industry funding (Sponsor bias)2 
 
• Low risk of bias, if the trial was not funded by a drug manufacturer. 
 
• High risk of bias, if the trial was funded by a drug manufacturer. 
 
• Unclear risk of bias, if the source of funding was unclear. 
 
Author-industry financial ties and/or employment (Other bias)2 
 
• Low risk of bias, if any authors did not disclose financial ties and/or employment by 
the pharmaceutical industry. 
• High risk of bias, if any authors disclose financial ties and/or employment by the 
pharmaceutical industry. 
• Unclear risk of bias, if author-industry financial ties or affiliation were not reported. 
 
 
 
Reference 
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trials. BMJ. 2011;343:d5928. 
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Item S3    Statistical method 
 
(A short summary, see details http://www.mtm.uoi.gr. and http://www.nicedsu.org.uk.) 
 
1. Bayesian approach and Credible intervals (CrI) 
 
The Bayesian approach utilizes both sample data and prior knowledge in estimating 
validity and weights each in proportion to its information value. The sample 
information is combined with the prior distribution to produce a posterior distribution, 
the mean of which is then taken as the estimate of the parameter of interest, in this case, 
test validity. Confidence intervals—called credible intervals by Bayesians—can be 
placed around this mean1. 
Confidence intervals (CI) usually is used in conventional non-Bayesian statistical 
analysis to indicate the precision of an estimate (for example, estimate of effect size). 
Credible intervals (CrI) in Bayesian statistics could be considered as analogous to 
confidence interval (CI) in non-Bayesian (or frequentist) statistical analysis, reflecting 
the precision of an estimate. A 95% credible interval can be interpreted as the following: 
there is 95% probability that the true treatment effect lies in a 95% credible interval.2,3 
2. Model interpretation 
 
Defining rik as the number of events (occurrence of CI-AKI), out of the total number of 
patients in each arm, nik, for arm k of trial i, we assume that the data generation process 
follows a Binomial likelihood i.e. 
rik~ Binomial(pik ,nik ) 
 
where  pik   represents  the  probability  of  an  event  in  arm  k  of  trial  i (i=1,2…139; 
 
k=1,2,3,4). pik  can only take values between 0 and 1. We model the probabilities of 
events pik on the logit scale as 
 
logit(pik)=μi+δi,jkI{k≠1} (1) 
 
where 
 
I{u}=1 if u is true 
 
I{u}=0 otherwise 
 
In this setup, µi are trial-specific baselines, representing the log-odds of the outcome in 
the ‘control’ treatment, δi,jk are the trial-specific log-odds ratios of events on the 
treatment group k compared to j. 
Parameterization of the model: 
 
The probabilities of event in the arms of a study pik can be parameterized in terms of 
the log-odds ratios (OR). The underlying trial-specific effect are defined as θi,jk; the 
log(OR) of treatment k relative to j in study i. 
Random effects model: 
 
For a random effects model the trial-specific log-odds ratios come from a common 
distribution: 
δi,jk ~ N (djk,σ2) 
 
where djk is the multiple-treatments meta-analysis estimate of the relative effect of 
treatment j relative to k and σ is the heterogeneity standard deviation assumed common 
across comparisons. 
Fixed effect model: 
 
For a fixed effect model we replace equation (1) with 
 
logit(pik)=μi+dikI{k≠1} 
which is equivalent to setting the between-trial heterogeneity σ2 to zero thus assuming 
homogeneity of the underlying true treatment effects. 
Consistency model: 
 
Assuming consistency, the means of the random effects distribution are related. 
Selecting T-1 basic parameters μAk, all means are related via μjk=μAk-μAj. 
Inconsistency model: 
 
In a random effects inconsistency model, no association between the μAks are assumed, 
so the model is a series of independent comparison-specific meta-analyses which 
however share the same heterogeneity parameter σ2. 
In a fixed effects inconsistency model no shared variance parameter needs to be 
considered. The inconsistency model is then equivalent to performing completely 
separate pairwise meta-analysis of the data. 
Meta-regression and subgroup model: 
 
The model specification considered is to assume that all treatment by covariate 
interactions (for all treatments vs the common control comparator) are identical; that is, 
the same regression coefficient (β) is assumed regardless of treatment (excluding 
control) implying the same covariate effect for each treatment relative to control. A 
prior distribution is given for the common regression coefficient. 
 
 
 
 
μ jb is the log odds of an event in trial j on ‘baseline’ treatment b, jbk is the trial-specific 
log odds ratio of treatment k relative to treatment b in trial j. The pooled log odds ratios, 
dbk, are identified by expressing them in terms of the reference treatment A, dAk −dAb, 
where dAA is set equal to zero. The between-study variance 2  is assumed constant for 
all treatment comparisons.4 
 
 
 
SUCRA 
 
The treatments can be ranked according to their effectiveness. The order of treatment 
in every MCMC circle is calculated as 
 
 
 
where I (dj≤dk)=1 if dj≤dk and 0 otherwise. The probability of treatment k to be at the j 
order is estimated from the quantity effectivenessk,j  and the cumulative probabilities 
by cum.effectivenessk.j. Then the surface under the cumulative ranking curve (SUCRA) 
for the treatment is 
 
 
3. Model fit 
 
We checked whether a model’s fit is satisfactory using the deviance information 
criterion (DIC). DIC is the sum of Dbar (the posterior mean residual deviance) and the 
leverage, Pd (also termed the effective number of parameters). The model fits the data 
𝑑𝑖𝑟 
𝑖𝑛𝑑 
𝑖𝑛𝑑 
𝑑𝑖𝑟 
adequately when Dbar is approximative with the number of data points. Pd provides a 
measure of model complexity. Then the DIC means a measure of model fit that 
penalizes model complexity – lower values of the DIC suggest a more parsimonious 
model. 
In order to assess whether the model provided adequate fit, we calculated DICs of four 
models, including random consistency, random inconsistency, fixed consistency, fixed 
inconsistency model within a Bayesian framework using the WinBUGS and R software. 
4. Assessment of inconsistency 
A “direct” estimate of the C vs. B effect,  ?̂?𝐵𝐶  , is to be compared to an “indirect” 
estimate, ?̂?𝐵𝐶  , formed from the AB and AC direct evidence 
 
𝑖𝑛𝑑  =  ?̂?𝑑𝑖𝑟  −  ?̂?𝑑𝑖𝑟 
?̂?𝐵𝐶 𝐴𝐶 𝐴𝐵 
 
𝑉𝑎𝑟(?̂?𝐵𝐶  ) = 𝑉𝑎𝑟(?̂? 𝑑𝑖𝑟 ) + 𝑉𝑎𝑟(?̂? 𝑑𝑖𝑟) 
𝐴𝐶 𝐴𝐵 
 
We assume that the direct estimates can either be estimates from individual trials. An 
estimate of the inconsistency, ω, can be formed by simply subtracting the direct and 
indirect estimates: 
?̂?𝐵𝐶  = ?̂?𝐵𝐶 
𝑖𝑛𝑑 
𝐵𝐶 
 
 
 
An approximate test of the null hypothesis that there is no inconsistency can be obtained 
 
by referring   to the standard normal distribution. the method can only 
be applied to 3 independent sources of data. Obviously, the method can only be applied 
to 3 independent sources of data. This idea can be extended to all loops formed in  the 
− ?̂? 
network and plot the ω together with its 95% confidence interval. In the presence of 
consistency within a loop all intervals should be compatible with zero. 
Another way to infer about consistency in the network as a whole is to compare the 
DICs between the consistency and inconsistency model. If the DIC assuming 
inconsistency is lower than the DIC assuming consistency by three or more units, then 
the assumption of consistency is likely to be violated. 
 
 
Reference: 
 
1. Schmidt FL, Hunter JE. Development of a general solution to the problem of 
validity generalization. J Appl Psychol. 1977;62(5):529-540. 
2. Whitener EM. Confusion of confidence intervals and credibility intervals in meta- 
analysis. J Appl Psychol. 1990;75(3):315-321. 
3. Caird JK, Willness CR, Steel P, Scialfa C. A meta-analysis of the effects of cell 
phones on driver performance. Accid Anal Prev. 2008;40(4):1282-1293. 
4. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study 
heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke 
prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 
2009;28(14):1861-1881
